PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33375412-3	2020	Considering these results, we wanted to take benefit of the structural analogy lying in donepezil (DPZ) and rasagiline, two indane derivatives marketed as AChE and MAO-B inhibitors, respectively, and to propose the synthesis and the preliminary in vitro biological characterization of a structural compromise between these two compounds, we called propargylaminodonepezil (PADPZ).	rasagiline	108-118	acetylcholinesterase (Cartwright blood group)	Homo sapiens	155-159
33614888-0	2021	Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer"s dementia.	rasagiline	0-10	microtubule associated protein tau	Homo sapiens	57-60
33887441-3	2021	Herein we report 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as hMAO-B inhibitors, which were designed by employing a fragment-based drug design strategy to link rasagiline to hydrophobic fragments.	rasagiline	184-194	monoamine oxidase B	Homo sapiens	86-92
33887441-4	2021	Among the synthesized 31 compounds, K8 and K24 demonstrated very encouraging hMAO-B inhibitory activities and selectivity over hMAO-A, better than rasagiline and safinamide.	rasagiline	147-157	keratin 24	Homo sapiens	43-46
33375412-3	2020	Considering these results, we wanted to take benefit of the structural analogy lying in donepezil (DPZ) and rasagiline, two indane derivatives marketed as AChE and MAO-B inhibitors, respectively, and to propose the synthesis and the preliminary in vitro biological characterization of a structural compromise between these two compounds, we called propargylaminodonepezil (PADPZ).	rasagiline	108-118	monoamine oxidase B	Homo sapiens	164-169
32652406-0	2020	Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-beta aggregation against Alzheimer"s disease.	rasagiline	47-57	monoamine oxidase B	Homo sapiens	105-124
32752896-3	2020	When compared to the modest selectivity index of rasagiline (II, a well-known MAO-B inhibitor, SI > 50), both 4b and 4e also showed better selectivity indices (SI > 60 and 120, respectively).	rasagiline	49-59	monoamine oxidase B	Homo sapiens	78-83
32037726-0	2020	Coumarin-rasagiline hybrids as potent and selective hMAO-B inhibitors, antioxidants and neuroprotective agents.	rasagiline	0-19	monoamine oxidase B	Homo sapiens	52-58
32858935-0	2020	Hydride Abstraction as the Rate-Limiting Step of the Irreversible Inhibition of Monoamine Oxidase B by Rasagiline and Selegiline: A Computational Empirical Valence Bond Study.	rasagiline	103-113	monoamine oxidase B	Homo sapiens	80-99
32086070-1	2020	To investigate whether the reversible MAO-B inhibitor and sodium channel blocker safinamide impairs glutamate release under parkinsonian conditions in vivo, and this effect is dependent on MAO-B inhibition, safinamide (and rasagiline as a comparator) were administered to 6-hydroxydopamine hemilesioned rats, a model of Parkinson"s disease, and haloperidol-treated rats, a model of neuroleptic-induced parkinsonism.	rasagiline	223-233	monoamine oxidase B	Rattus norvegicus	38-43
32086070-3	2020	Glutamate and GABA release was stimulated by reverse dialysis of veratridine, and safinamide or rasagiline were acutely administered before veratridine at doses inhibiting MAO-B >50%.	rasagiline	96-106	monoamine oxidase B	Rattus norvegicus	172-177
32086070-9	2020	MAO-B inhibitors safinamide and rasagiline differ in their abilities to inhibit depolarization-evoked glutamate release in the basal ganglia of parkinsonian rats.	rasagiline	32-42	monoamine oxidase B	Rattus norvegicus	0-5
32048262-0	2020	A new MAP-Rasagiline conjugate reduces alpha-synuclein inclusion formation in a cell model.	rasagiline	6-20	synuclein alpha	Homo sapiens	39-54
32048262-6	2020	METHODS: Here, we synthesized solid-phase CPPs using an amphipathic model peptide (MAP) conjugated with the drug Rasagiline (RAS), which we named RAS-MAP, and evaluated its effect on alpha-syn inclusion formation in a human cell-based model of synucleinopathy.	rasagiline	113-123	synuclein alpha	Homo sapiens	183-192
32048262-7	2020	RESULTS: We found that treatment with RAS-MAP at low concentrations (1-3 microM) reduced alpha-syn aggregation in cells.	rasagiline	38-41	synuclein alpha	Homo sapiens	89-98
31993732-0	2020	Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate alpha-synuclein cytotoxicity in disease-modifying therapy for Parkinson"s disease.	rasagiline	0-10	synuclein alpha	Homo sapiens	102-117
32070917-5	2020	Although some of the tetralinamines 6 and indanamines 7 showed very high GluN2B affinity (e.g. Ki (7f) = 3.2 nM), they could not inhibit glutamate/glycine inducted cytotoxicity.	rasagiline	42-53	glutamate ionotropic receptor NMDA type subunit 2B	Homo sapiens	73-79
31993732-6	2020	Selegiline and rasagiline, inhibitors of type B monoamine oxidase, have been proved to exhibit potent neuroprotective function: regulation of mitochondrial apoptosis system, maintenance of mitochondrial function, increased expression of genes coding antioxidant enzymes, anti-apoptotic Bcl-2 and pro-survival NTFs, and suppression of oligomerization and aggregation of alpha-synuclein and the toxicity in cellular and animal experiments.	rasagiline	15-25	BCL2 apoptosis regulator	Homo sapiens	286-291
31993732-6	2020	Selegiline and rasagiline, inhibitors of type B monoamine oxidase, have been proved to exhibit potent neuroprotective function: regulation of mitochondrial apoptosis system, maintenance of mitochondrial function, increased expression of genes coding antioxidant enzymes, anti-apoptotic Bcl-2 and pro-survival NTFs, and suppression of oligomerization and aggregation of alpha-synuclein and the toxicity in cellular and animal experiments.	rasagiline	15-25	synuclein alpha	Homo sapiens	369-384
31463990-2	2019	The present study aimed to investigate the effects of rasagiline on regional cerebral blood flow (rCBF) in patients with PD using single-photon emission computed tomography (SPECT).	rasagiline	54-64	CCAAT/enhancer binding protein zeta	Rattus norvegicus	98-102
32250219-5	2020	TV-3326 combines the neurorestorative/neuroprotective actions of the cholinesterase (ChE) inhibitory activity of rivastigmine with rasagiline (a selective monoamine oxidase-B inhibitor and novel antiparkinsonian agent) in a single molecule.	rasagiline	131-141	monoamine oxidase B	Homo sapiens	155-174
32378642-5	2020	Rasagiline is a potent and specific MAO-B inhibitor and is currently approved as an antiparkinsonian drug in more than 50 countries, including the United States and European countries.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	36-41
31463990-7	2019	Changes in rCBF were compared between the rasagiline group and the comparison group in a voxel-wise manner.	rasagiline	42-52	CCAAT/enhancer binding protein zeta	Rattus norvegicus	11-15
31463990-9	2019	A significant group-by-time interaction effect on rCBF was found in the right precuneus (P = .001), where rCBF was decreased in the comparison group and remained stable in the rasagiline group.	rasagiline	176-186	CCAAT/enhancer binding protein zeta	Rattus norvegicus	50-54
31463990-9	2019	A significant group-by-time interaction effect on rCBF was found in the right precuneus (P = .001), where rCBF was decreased in the comparison group and remained stable in the rasagiline group.	rasagiline	176-186	CCAAT/enhancer binding protein zeta	Rattus norvegicus	106-110
30689042-1	2019	Rasagiline is a monoamine oxidase B inhibitor with demonstrated efficacy and safety in patients with Parkinson"s disease (PD).	rasagiline	0-10	monoamine oxidase B	Homo sapiens	16-35
31264403-3	2019	Still, despite this practical importance, the precise chemical mechanisms underlying the irreversible inhibition of the MAO B isoform with clinical drugs rasagiline (RAS) and selegiline (SEL) remained unknown.	rasagiline	154-164	monoamine oxidase B	Homo sapiens	120-125
31264403-3	2019	Still, despite this practical importance, the precise chemical mechanisms underlying the irreversible inhibition of the MAO B isoform with clinical drugs rasagiline (RAS) and selegiline (SEL) remained unknown.	rasagiline	166-169	monoamine oxidase B	Homo sapiens	120-125
31421966-1	2019	The irreversible monoamine oxidase B (MAO B) inhibitor rasagiline has been described with multiple disease modifying effects in vitro on models of Parkinson"s disease.	rasagiline	55-65	monoamine oxidase B	Homo sapiens	17-36
31421966-1	2019	The irreversible monoamine oxidase B (MAO B) inhibitor rasagiline has been described with multiple disease modifying effects in vitro on models of Parkinson"s disease.	rasagiline	55-65	monoamine oxidase B	Homo sapiens	38-43
30877626-1	2019	Rasagiline mesylate is an irreversible MAO-B inhibitor which requires daily oral administration for treatment of Parkinson"s disease due to its short half-life.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	39-44
30359642-5	2019	We also tested another propargylamine MAO-B inhibitor, rasagiline.	rasagiline	55-65	monoamine oxidase B	Mus musculus	38-43
30205936-1	2019	BACKGROUND: Rasagiline is a monoamine oxidase type-B inhibitor in development in Japan for Parkinson"s disease (PD).	rasagiline	12-22	monoamine oxidase B	Homo sapiens	28-52
30579934-6	2019	DOPAL-induced alpha-synuclein aggregates were resolved in the presence and absence of rasagiline or aminoindan using quantitative Western blotting.	rasagiline	86-96	synuclein alpha	Rattus norvegicus	14-29
30579934-10	2019	Rasagiline and aminoindan significantly reduced aggregation of alpha-synuclein of all sizes in test tube and PC-12 cells experiments.	rasagiline	0-10	synuclein alpha	Rattus norvegicus	63-78
30359642-7	2019	In the hippocampus and prefrontal cortex of mice subjected to the FST, selegiline and rasagiline completely inhibited MAO-B activities.	rasagiline	86-96	monoamine oxidase B	Mus musculus	118-123
31795034-0	2019	Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [18F]THK5351 uptake in progressive supranuclear palsy.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	14-33
30192007-1	2019	INTRODUCTION: Rasagiline is a monoamine oxidase B (MAO-B) inhibitor with possible neuroprotective effects in patients with amyotrophic lateral sclerosis (ALS).	rasagiline	14-24	monoamine oxidase B	Homo sapiens	30-49
30192007-1	2019	INTRODUCTION: Rasagiline is a monoamine oxidase B (MAO-B) inhibitor with possible neuroprotective effects in patients with amyotrophic lateral sclerosis (ALS).	rasagiline	14-24	monoamine oxidase B	Homo sapiens	51-56
30160213-4	2019	Selegiline and rasagiline are irreversible inhibitors forming a covalent bond within the active site of MAOB.	rasagiline	15-25	monoamine oxidase B	Homo sapiens	104-108
31795034-3	2019	OBJECTIVES: To test the hypothesis that the MAO-B inhibitor, rasagiline reduces [18F]THK5351 uptake in PSP.	rasagiline	61-71	monoamine oxidase B	Homo sapiens	44-49
30341696-6	2018	Selective inhibitors of MAO-B (selegiline, rasagiline and safinamide) have found a therapeutic role in the treatment of Parkinson"s disease and reversible inhibitors of MAO-A offered antidepressant activity without the serious side effects of the earlier nonselective MAO inhibitors.	rasagiline	43-53	monoamine oxidase B	Homo sapiens	24-29
30534374-1	2018	Background: Rasagiline is a monoamine oxidase-B inhibitor used for Parkinson"s disease (PD) treatment, but its effectiveness on Chinese patients is unclear.	rasagiline	12-22	monoamine oxidase B	Homo sapiens	28-47
29279995-7	2018	MAO-B inhibitors selegiline and rasagiline protect neurons via increase expression of anti-apoptotic Bcl-2 and pro-survival neurotrophic factors in human neuroblastoma SH-SY5Y and glioblastoma U118MG cell lines.	rasagiline	32-42	monoamine oxidase B	Homo sapiens	0-5
30341696-6	2018	Selective inhibitors of MAO-B (selegiline, rasagiline and safinamide) have found a therapeutic role in the treatment of Parkinson"s disease and reversible inhibitors of MAO-A offered antidepressant activity without the serious side effects of the earlier nonselective MAO inhibitors.	rasagiline	43-53	monoamine oxidase A	Homo sapiens	169-174
29279995-7	2018	MAO-B inhibitors selegiline and rasagiline protect neurons via increase expression of anti-apoptotic Bcl-2 and pro-survival neurotrophic factors in human neuroblastoma SH-SY5Y and glioblastoma U118MG cell lines.	rasagiline	32-42	BCL2 apoptosis regulator	Homo sapiens	101-106
29955193-7	2018	Data Synthesis: The search identified 8 studies evaluating the potential interaction between SSRIs and the MAO-B inhibitors selegiline and rasagiline.	rasagiline	139-149	monoamine oxidase B	Homo sapiens	107-112
29279995-8	2018	MAO-A knockdown suppressed the rasagiline-induced gene expression in SH-SY5Y cells, whereas MAO-B silencing enhanced the basal- and selegiline-induced gene expression in U118MG cells.	rasagiline	31-41	monoamine oxidase A	Homo sapiens	0-5
29417334-0	2018	Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson"s disease.	rasagiline	104-114	monoamine oxidase B	Homo sapiens	71-76
29417334-8	2018	The second MAO-B inhibitor approved for the treatment of Parkinson"s disease, rasagiline also possesses this structural element and shows similar pharmacological characteristics.	rasagiline	78-88	monoamine oxidase B	Homo sapiens	11-16
29956417-0	2018	Rasagiline, an inhibitor of MAO-B, decreases colonic motility through elevating colonic dopamine content.	rasagiline	0-10	monoamine oxidase B	Rattus norvegicus	28-33
29956417-3	2018	Rasagiline, an irreversible MAO-B inhibitor, is used to treat Parkinson"s disease because of its neuroprotective effect and increasing central DA.	rasagiline	0-10	monoamine oxidase B	Rattus norvegicus	28-33
29956417-8	2018	The rasagiline-treated rats also manifested decreased MAO-B activity and increased DA content in the colonic muscular layer, but no alterations were detected in the protein expressions of D1 and D2 receptors, and MAO-A and MAO-B, as well as in the content of 5-hydroxytryptamine and noradrenaline.	rasagiline	4-14	monoamine oxidase B	Rattus norvegicus	54-59
29956417-11	2018	Long-term administration of rasagiline can increase colonic DA thereby inhibiting colonic motility, suggesting that colonic MAO-B could be a potential drug target for colonic dysmotility.	rasagiline	28-38	monoamine oxidase B	Homo sapiens	124-129
29769405-5	2018	Accordingly, overexpression of AEP in SNCA transgenic mice elicits alpha-Syn N103 cleavage and accelerates PD pathogenesis, and inhibition of MAO-B by Rasagiline diminishes alpha-Syn-mediated PD pathology and motor dysfunction.	rasagiline	151-161	monoamine oxidase B	Mus musculus	142-147
29477356-2	2018	The objective of this study was to investigate anodal co-iontophoresis of pramipexole (PRAM; dopamine agonist) and rasagiline (RAS; MAO-B inhibitor) in vitro and in vivo.	rasagiline	127-130	monoamine oxidase B	Homo sapiens	132-137
29847694-11	2018	When ranking the MAO-B inhibitors given in combination with levodopa, selegiline was the most effective and rasagiline was the second best.	rasagiline	108-118	monoamine oxidase B	Homo sapiens	17-22
29934198-1	2018	BACKGROUND: Rasagiline, a monoamine oxidase B inhibitor with neuroprotective potential in Parkinson"s disease, has shown a disease-modifying effect in the SOD1-Gly93Ala low-expressing mouse model of amyotrophic lateral sclerosis, both alone and in combination with riluzole.	rasagiline	12-22	monoamine oxidase B	Mus musculus	26-45
29934198-1	2018	BACKGROUND: Rasagiline, a monoamine oxidase B inhibitor with neuroprotective potential in Parkinson"s disease, has shown a disease-modifying effect in the SOD1-Gly93Ala low-expressing mouse model of amyotrophic lateral sclerosis, both alone and in combination with riluzole.	rasagiline	12-22	superoxide dismutase 1, soluble	Mus musculus	155-159
29748109-1	2018	INTRODUCTION: Rasagiline, a selective, irreversible monoamine oxidase-B inhibitor, is in development in Japan as adjunctive therapy to levodopa.	rasagiline	14-24	monoamine oxidase B	Homo sapiens	52-71
29159774-1	2018	BACKGROUND AND OBJECTIVES: Rasagiline tablet is an oral MAO-B inhibitor applied in early or advanced Parkinson"s disease (PD).	rasagiline	27-37	monoamine oxidase B	Homo sapiens	56-61
29372592-0	2018	Rasagiline delays retinal degeneration in a mouse model of retinitis pigmentosa via modulation of Bax/Bcl-2 expression.	rasagiline	0-10	BCL2-associated X protein	Mus musculus	98-101
29372592-0	2018	Rasagiline delays retinal degeneration in a mouse model of retinitis pigmentosa via modulation of Bax/Bcl-2 expression.	rasagiline	0-10	B cell leukemia/lymphoma 2	Mus musculus	102-107
29372592-4	2018	Rasagiline is an antiparkinsonian drug that has shown neuroprotective effects in part attributed to a modulation of Bax/Bcl-2 expression.	rasagiline	0-10	BCL2-associated X protein	Mus musculus	116-119
29372592-4	2018	Rasagiline is an antiparkinsonian drug that has shown neuroprotective effects in part attributed to a modulation of Bax/Bcl-2 expression.	rasagiline	0-10	B cell leukemia/lymphoma 2	Mus musculus	120-125
29372592-9	2018	In addition, the expression of proapoptotic Bax decreased, whereas the antiapoptotic factor Bcl-2 increased after rasagiline treatment.	rasagiline	114-124	B cell leukemia/lymphoma 2	Mus musculus	92-97
29339253-0	2018	Design, synthesis and bioevalucation of novel 2,3-dihydro-1H-inden-1-amine derivatives as potent and selective human monoamine oxidase B inhibitors based on rasagiline.	rasagiline	157-167	monoamine oxidase B	Homo sapiens	117-136
29339253-2	2018	Herein we report rasagiline derivatives as novel potent and selective hMAO-B inhibitors.	rasagiline	17-27	monoamine oxidase B	Homo sapiens	70-76
29339253-3	2018	They were designed by employing fragment-based drug design strategy to link rasagiline and hydrophobic fragments, which may target a hydrophobic pocket in the entrance cavity of hMAO-B.	rasagiline	76-86	monoamine oxidase B	Homo sapiens	178-184
29339253-5	2018	A promising selective hMAO-B inhibitor D14 with similar inhibitory activity as rasagiline and improved isoform selectivity was yielded.	rasagiline	79-89	monoamine oxidase B	Homo sapiens	22-28
29257285-7	2018	Immunohistochemistry and western blot analysis revealed that treatment with rasagiline positively regulated early-stage PD pathogenesis by downregulating the expression of JNK3 and upregulating caspase-3; however, there was no positive effect on the advanced stages of PD.	rasagiline	76-86	mitogen-activated protein kinase 10	Mus musculus	172-176
29257285-7	2018	Immunohistochemistry and western blot analysis revealed that treatment with rasagiline positively regulated early-stage PD pathogenesis by downregulating the expression of JNK3 and upregulating caspase-3; however, there was no positive effect on the advanced stages of PD.	rasagiline	76-86	caspase 3	Mus musculus	194-203
29257285-8	2018	Overall, these results concluded that rasagiline has the ability to inhibit the expression of JNK3 and upregulate caspase-3 in early stages of PD; however, rasagline appears to have no impact on JNK3 and caspase-3 levels in the advanced stages of PD.	rasagiline	38-48	mitogen-activated protein kinase 10	Mus musculus	94-98
29257285-8	2018	Overall, these results concluded that rasagiline has the ability to inhibit the expression of JNK3 and upregulate caspase-3 in early stages of PD; however, rasagline appears to have no impact on JNK3 and caspase-3 levels in the advanced stages of PD.	rasagiline	38-48	caspase 3	Mus musculus	114-123
28923922-8	2017	Accordingly, MAO-B inhibitor rasagiline disrupts alpha-Syn/TrkB complex and rescues TrkB neurotrophic signaling, preventing alpha-Syn-induced dopaminergic neuronal death and restoring motor functions.	rasagiline	29-39	monoamine oxidase B	Homo sapiens	13-18
29464559-3	2018	Currently, the treatment of Parkinson"s disease involves the use of selective MAO B inhibitors such as rasagiline and safinamide.	rasagiline	103-113	monoamine oxidase B	Homo sapiens	78-83
29552298-0	2018	Synergistic neuroprotective effect of rasagiline and idebenone against retinal ischemia-reperfusion injury via the Lin28-let-7-Dicer pathway.	rasagiline	38-48	lin-28 homolog A	Homo sapiens	115-120
29552298-6	2018	Furthermore, idebenone and rasagiline induced the expression of Lin28A and Lin28B, respectively, which resulted in a reduced expression of microRNAs in the let-7 family and an increased protein output of Dicer.	rasagiline	27-37	lin-28 homolog A	Homo sapiens	64-70
29552298-6	2018	Furthermore, idebenone and rasagiline induced the expression of Lin28A and Lin28B, respectively, which resulted in a reduced expression of microRNAs in the let-7 family and an increased protein output of Dicer.	rasagiline	27-37	lin-28 homolog B	Homo sapiens	75-81
28923922-8	2017	Accordingly, MAO-B inhibitor rasagiline disrupts alpha-Syn/TrkB complex and rescues TrkB neurotrophic signaling, preventing alpha-Syn-induced dopaminergic neuronal death and restoring motor functions.	rasagiline	29-39	synemin	Homo sapiens	55-58
28923922-8	2017	Accordingly, MAO-B inhibitor rasagiline disrupts alpha-Syn/TrkB complex and rescues TrkB neurotrophic signaling, preventing alpha-Syn-induced dopaminergic neuronal death and restoring motor functions.	rasagiline	29-39	neurotrophic receptor tyrosine kinase 2	Homo sapiens	59-63
28923922-8	2017	Accordingly, MAO-B inhibitor rasagiline disrupts alpha-Syn/TrkB complex and rescues TrkB neurotrophic signaling, preventing alpha-Syn-induced dopaminergic neuronal death and restoring motor functions.	rasagiline	29-39	neurotrophic receptor tyrosine kinase 2	Homo sapiens	84-88
28923922-8	2017	Accordingly, MAO-B inhibitor rasagiline disrupts alpha-Syn/TrkB complex and rescues TrkB neurotrophic signaling, preventing alpha-Syn-induced dopaminergic neuronal death and restoring motor functions.	rasagiline	29-39	synuclein alpha	Homo sapiens	49-58
28682929-9	2017	In view of the observed, considerable heterogeneity of enzyme activities, we suggest to determine activities of monoamine oxidase A and B to reduce the risk for tyramine-induced hypertension and the serotonergic syndrome during chronic therapy with rasagiline or safinamide.	rasagiline	249-259	monoamine oxidase A	Homo sapiens	112-131
28682929-2	2017	Rasagiline is an irreversible inhibitor of monoamine oxidase B.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	43-62
28299453-4	2017	We confirm with this design, that rasagiline and selegiline inhibit monoamine oxidase-B but not monoamine oxidase-A after single dosing.	rasagiline	34-44	monoamine oxidase B	Homo sapiens	68-87
28682929-6	2017	Patients on rasagiline or safinamide showed lower monoamine oxidase-B enzyme activity compared with patients without monoamine oxidase B inhibitor intake.	rasagiline	12-22	monoamine oxidase B	Homo sapiens	50-69
28682929-6	2017	Patients on rasagiline or safinamide showed lower monoamine oxidase-B enzyme activity compared with patients without monoamine oxidase B inhibitor intake.	rasagiline	12-22	monoamine oxidase B	Homo sapiens	117-136
28577058-0	2017	Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline.	rasagiline	215-225	BCL2 apoptosis regulator	Homo sapiens	84-89
28577058-2	2017	MAO-B inhibitors, rasagiline and selegiline [(-)deprenyl], protect neurons in animal and cellular models of neurodegeneration.	rasagiline	18-28	monoamine oxidase B	Homo sapiens	0-5
28577058-3	2017	However, the role of MAO-B itself in the regulation of cell death processing remains elusive, whereas type A MAO (MAO-A) mediates the induction of anti-apoptotic Bcl-2 genes by rasagiline and selegiline.	rasagiline	177-187	monoamine oxidase A	Homo sapiens	114-119
28577058-3	2017	However, the role of MAO-B itself in the regulation of cell death processing remains elusive, whereas type A MAO (MAO-A) mediates the induction of anti-apoptotic Bcl-2 genes by rasagiline and selegiline.	rasagiline	177-187	BCL2 apoptosis regulator	Homo sapiens	162-167
28577058-5	2017	Selegiline significantly increased Mao-B, which was suppressed by Mao-A knockdown with short interfering (si)RNA, whereas rasagiline less markedly increased Mao-B, which was not affected by Mao-A knockdown.	rasagiline	122-132	monoamine oxidase B	Homo sapiens	157-162
28577058-6	2017	Mao-A mRNA was also markedly increased by rasagiline and selegiline, and Mao-B knockdown significantly enhanced the induction by selegiline, but not by rasagiline.	rasagiline	42-52	monoamine oxidase A	Homo sapiens	0-5
28577058-9	2017	Rasagiline increased BDNF and GDNF, which Mao-B and Mao-A knockdown inhibited.	rasagiline	0-10	brain derived neurotrophic factor	Homo sapiens	21-25
28577058-9	2017	Rasagiline increased BDNF and GDNF, which Mao-B and Mao-A knockdown inhibited.	rasagiline	0-10	glial cell derived neurotrophic factor	Homo sapiens	30-34
28577058-9	2017	Rasagiline increased BDNF and GDNF, which Mao-B and Mao-A knockdown inhibited.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	42-47
28577058-9	2017	Rasagiline increased BDNF and GDNF, which Mao-B and Mao-A knockdown inhibited.	rasagiline	0-10	monoamine oxidase A	Homo sapiens	52-57
28577058-10	2017	These results show that MAO-B might function as a repressor and MAO-A as a mediator in the constitutional expression of pro-survival genes, and that MAO-B and MAO-A might regulate different signal pathways for rasagiline and selegiline to induce neuroprotective genes.	rasagiline	210-220	monoamine oxidase B	Homo sapiens	24-29
28577058-10	2017	These results show that MAO-B might function as a repressor and MAO-A as a mediator in the constitutional expression of pro-survival genes, and that MAO-B and MAO-A might regulate different signal pathways for rasagiline and selegiline to induce neuroprotective genes.	rasagiline	210-220	monoamine oxidase B	Homo sapiens	149-154
28577058-10	2017	These results show that MAO-B might function as a repressor and MAO-A as a mediator in the constitutional expression of pro-survival genes, and that MAO-B and MAO-A might regulate different signal pathways for rasagiline and selegiline to induce neuroprotective genes.	rasagiline	210-220	monoamine oxidase A	Homo sapiens	159-164
28293967-1	2017	OBJECTIVE: Rasagiline is a second-generation potent selective inhibitor of monoamine oxidase-B.	rasagiline	11-21	monoamine oxidase B	Homo sapiens	75-94
28550482-1	2017	Monoamine oxidase type B (MAO-B) inhibitors, such as selegiline and rasagiline, can be used as monotherapy or adjuvant therapy to levodopa in Parkinson"s disease (PD).	rasagiline	68-78	monoamine oxidase B	Homo sapiens	0-24
28550482-1	2017	Monoamine oxidase type B (MAO-B) inhibitors, such as selegiline and rasagiline, can be used as monotherapy or adjuvant therapy to levodopa in Parkinson"s disease (PD).	rasagiline	68-78	monoamine oxidase B	Homo sapiens	26-31
27503749-9	2016	The detection of MAO inhibition through this method showed that IC50 values of rasagiline are 8.00 x 10(-9) M for MAO-B and 2.59 x 10(-7) M for MAO-A.	rasagiline	79-89	monoamine oxidase A	Rattus norvegicus	17-20
28301816-8	2017	The reference drugs selegiline (IC50 = 0.040 muM) and rasagiline (IC50 = 0.066 muM) also displayed a significant inhibition against hMAO-B.	rasagiline	54-64	monoamine oxidase B	Homo sapiens	132-138
28148284-4	2017	Recently, her Stalevo had been changed to rasagiline (a monoamine oxidase B inhibitor).	rasagiline	42-52	monoamine oxidase B	Homo sapiens	56-75
30566307-9	2017	Rasagiline is a widely used MAO-B inhibitor in many countries.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	28-33
27108605-7	2016	RESULTS: Patients treated with rasagiline had a statistically significant decrease in FoG-Q score and modified MDS UPDRS score after 1, 2 and 3 months of therapy.	rasagiline	31-41	zinc finger protein, FOG family member 1	Homo sapiens	86-89
27108605-9	2016	We also observed a statistically significant improvement in global QoL and in the subscales mobility, ADL, stigma and bodily discomfort in patients after 3 months of rasagiline therapy.	rasagiline	166-176	sarcoglycan alpha	Homo sapiens	102-105
27503749-9	2016	The detection of MAO inhibition through this method showed that IC50 values of rasagiline are 8.00 x 10(-9) M for MAO-B and 2.59 x 10(-7) M for MAO-A.	rasagiline	79-89	monoamine oxidase B	Rattus norvegicus	114-125
27503749-9	2016	The detection of MAO inhibition through this method showed that IC50 values of rasagiline are 8.00 x 10(-9) M for MAO-B and 2.59 x 10(-7) M for MAO-A.	rasagiline	79-89	monoamine oxidase A	Rattus norvegicus	144-149
30838260-0	2017	Rasagiline Sensitive Dopamine D2 Receptor Gene Variants: A Step Forward Toward More Personalized Antiparkinsonian Therapy.	rasagiline	0-10	dopamine receptor D2	Homo sapiens	21-41
27618783-1	2016	OBJECTIVES: Freezing of gait (FoG) is a challenging clinical symptom in Parkinson"s disease with variable improvements in FoG with rasagiline.	rasagiline	131-141	zinc finger protein, FOG family member 1	Homo sapiens	30-33
27618783-1	2016	OBJECTIVES: Freezing of gait (FoG) is a challenging clinical symptom in Parkinson"s disease with variable improvements in FoG with rasagiline.	rasagiline	131-141	zinc finger protein, FOG family member 1	Homo sapiens	122-125
27618783-10	2016	In this model, lower UPDRS gait scores, higher LEDD dose, lower anxiety scores, lower FOG-Q scores, and higher UPDRS scores for lower extremity rigidity and rise from chair, predicted FoG-related rasagiline benefit.	rasagiline	196-206	zinc finger protein, FOG family member 1	Homo sapiens	184-187
27618783-11	2016	CONCLUSION: Using both objective and subjective measures for FoG, the current pilot study identified a set of clinical variables that may elucidate the heterogeneous FoG-responsiveness following rasagiline treatment and aid in predicting improvement.	rasagiline	195-205	zinc finger protein, FOG family member 1	Homo sapiens	61-64
27618783-11	2016	CONCLUSION: Using both objective and subjective measures for FoG, the current pilot study identified a set of clinical variables that may elucidate the heterogeneous FoG-responsiveness following rasagiline treatment and aid in predicting improvement.	rasagiline	195-205	zinc finger protein, FOG family member 1	Homo sapiens	166-169
27318273-2	2016	Based on this rational, a new class of cholinesterase (ChE)-monoamine oxidase (MAO) inhibitors were designed and synthesized by amalgamating the propargyl moiety of the irreversible selective MAO-B inhibitor, neuroprotective/neurorestorative anti-Parkinsonian drug, rasagiline, into the "N-methyl" position of the ChE inhibitor, anti-AD drug rivastigmine.	rasagiline	266-276	butyrylcholinesterase	Homo sapiens	39-53
27318273-2	2016	Based on this rational, a new class of cholinesterase (ChE)-monoamine oxidase (MAO) inhibitors were designed and synthesized by amalgamating the propargyl moiety of the irreversible selective MAO-B inhibitor, neuroprotective/neurorestorative anti-Parkinsonian drug, rasagiline, into the "N-methyl" position of the ChE inhibitor, anti-AD drug rivastigmine.	rasagiline	266-276	butyrylcholinesterase	Homo sapiens	55-58
27318273-2	2016	Based on this rational, a new class of cholinesterase (ChE)-monoamine oxidase (MAO) inhibitors were designed and synthesized by amalgamating the propargyl moiety of the irreversible selective MAO-B inhibitor, neuroprotective/neurorestorative anti-Parkinsonian drug, rasagiline, into the "N-methyl" position of the ChE inhibitor, anti-AD drug rivastigmine.	rasagiline	266-276	monoamine oxidase B	Homo sapiens	192-197
27220335-5	2016	Rat pheochromocytoma PC12 cells were incubated with hydroxytyrosol (10 microM, 180 min) alone or with the MAO-A inhibitor clorgyline (1 nM) or the MAO-B inhibitors rasagiline or selegiline (0.5 microM).	rasagiline	164-174	monoamine oxidase B	Rattus norvegicus	147-152
27729794-1	2016	INTRODUCTION: Rasagiline is a selective, irreversible monoamine oxidase B inhibitor that ameliorates the symptoms of Parkinson"s disease (PD) by inhibiting striatal dopamine metabolism.	rasagiline	14-24	monoamine oxidase B	Homo sapiens	54-73
25604428-3	2016	It has been suggested that the irreversible MAO-B inhibitors selegiline and rasagiline exert a neuroprotective effect in Parkinson"s and Alzheimer"s diseases.	rasagiline	76-86	monoamine oxidase B	Homo sapiens	44-49
27190009-0	2016	Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson"s disease: a pharmacogenetic study.	rasagiline	51-61	dopamine receptor D2	Homo sapiens	0-20
27190009-7	2016	Single nucleotide polymorphisms, rs2283265 and rs1076560, in the dopamine D2 receptor gene (DRD2) were found to be significantly associated with a favourable peak response to rasagiline at 12 weeks in early Parkinson"s disease after controlling for multiple testing.	rasagiline	175-185	dopamine receptor D2	Homo sapiens	65-85
27190009-7	2016	Single nucleotide polymorphisms, rs2283265 and rs1076560, in the dopamine D2 receptor gene (DRD2) were found to be significantly associated with a favourable peak response to rasagiline at 12 weeks in early Parkinson"s disease after controlling for multiple testing.	rasagiline	175-185	dopamine receptor D2	Homo sapiens	92-96
26951202-1	2016	BACKGROUND AND OBJECTIVE: Although there is evidence indicating cytochome P450 (CYP) 1A2 is responsible for the metabolism of rasagiline, the role of other CYP isoforms is unclear.	rasagiline	126-136	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	74-88
27089850-1	2016	Rasagiline is a monoamine oxidase type B inhibitor that possesses no amphetamine-like properties, and provides symptomatic relief in early and late stages of Parkinson"s disease (PD).	rasagiline	0-10	monoamine oxidase B	Homo sapiens	16-40
27230855-2	2016	The MAO-B inhibitor rasagiline has shown neuroprotective effects in preclinical models of neurodegeneration.	rasagiline	20-30	monoamine oxidase B	Homo sapiens	4-9
27060436-1	2016	Rasagiline is a selective, irreversible inhibitor of monoamine oxidase type-B (MAO-B) and has been used both as a monotherapy and in addition to levodopa in the treatment of Parkinson"s disease (PD).	rasagiline	0-10	monoamine oxidase B	Homo sapiens	53-77
27060436-1	2016	Rasagiline is a selective, irreversible inhibitor of monoamine oxidase type-B (MAO-B) and has been used both as a monotherapy and in addition to levodopa in the treatment of Parkinson"s disease (PD).	rasagiline	0-10	monoamine oxidase B	Homo sapiens	79-84
27060436-2	2016	Rasagiline is metabolized by the cytochrome P450 (CYP) system, and the following three major metabolites with potential neuroprotective activity have been identified: 1-aminoindan (AI), 3-hydroxy-N-propargyl-1-aminoindan (3-OH-PAI) and 3-hydroxy-1-aminoindan (3-OH-AI).	rasagiline	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-48
27060436-2	2016	Rasagiline is metabolized by the cytochrome P450 (CYP) system, and the following three major metabolites with potential neuroprotective activity have been identified: 1-aminoindan (AI), 3-hydroxy-N-propargyl-1-aminoindan (3-OH-PAI) and 3-hydroxy-1-aminoindan (3-OH-AI).	rasagiline	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	50-53
27060436-2	2016	Rasagiline is metabolized by the cytochrome P450 (CYP) system, and the following three major metabolites with potential neuroprotective activity have been identified: 1-aminoindan (AI), 3-hydroxy-N-propargyl-1-aminoindan (3-OH-PAI) and 3-hydroxy-1-aminoindan (3-OH-AI).	rasagiline	0-10	serpin family B member 2	Homo sapiens	227-230
26897020-0	2016	Erratum to: Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline.	rasagiline	134-144	monoamine oxidase B	Homo sapiens	60-79
25604428-5	2016	There is increasing evidence that MAO-A activity, but not that of MAO-B, is implicated in the pathophysiology of neurodegenerative disorders, but also in gene induction by MAO-B inhibitors; on the other hand, selegiline and rasagiline increase MAO-A mRNA, protein, and enzyme activity levels.	rasagiline	224-234	monoamine oxidase B	Homo sapiens	172-177
26530401-2	2016	Rasagiline is a selective, monoamine oxidase-B inhibitor and it undergoes significant FPM in the liver prior to excretion by CYP1A2.	rasagiline	0-10	monoamine oxidase B	Rattus norvegicus	27-46
26607251-0	2016	BDNF levels are increased by aminoindan and rasagiline in a double lesion model of Parkinson s disease.	rasagiline	44-54	brain-derived neurotrophic factor	Rattus norvegicus	0-4
26607251-11	2016	BDNF levels were significantly increased in the hippocampus and striatum of the rasagiline- and aminoindan-lesioned groups compared to the saline-treated lesioned group.	rasagiline	80-90	brain-derived neurotrophic factor	Rattus norvegicus	0-4
26607251-12	2016	Double-lesioned rats treated with rasagiline or aminoindan exhibited a sparing in the mitochondrial marker Hsp60, suggesting mitochondrial involvement in neuroprotection.	rasagiline	34-44	heat shock protein family D (Hsp60) member 1	Rattus norvegicus	107-112
26607251-13	2016	Tyrosine hydroxylase (TH) immunohistochemistry revealed a sparing of TH-immunoreactive terminals in double-lesioned rats treated with rasagiline or aminoindan in the striatum, hippocampus, and substantia nigra.	rasagiline	134-144	tyrosine hydroxylase	Rattus norvegicus	0-20
26607251-13	2016	Tyrosine hydroxylase (TH) immunohistochemistry revealed a sparing of TH-immunoreactive terminals in double-lesioned rats treated with rasagiline or aminoindan in the striatum, hippocampus, and substantia nigra.	rasagiline	134-144	tyrosine hydroxylase	Rattus norvegicus	22-24
26607251-13	2016	Tyrosine hydroxylase (TH) immunohistochemistry revealed a sparing of TH-immunoreactive terminals in double-lesioned rats treated with rasagiline or aminoindan in the striatum, hippocampus, and substantia nigra.	rasagiline	134-144	tyrosine hydroxylase	Rattus norvegicus	69-71
26607251-14	2016	These data provide evidence of neuroprotection by aminoindan and rasagiline via their ability to enhance BDNF levels.	rasagiline	65-75	brain-derived neurotrophic factor	Rattus norvegicus	105-109
26635194-3	2016	Levodopa and monoamine oxidase inhibitors (rasagiline and selegiline) have shown effective improvement for FOG.	rasagiline	43-53	zinc finger protein, FOG family member 1	Homo sapiens	107-110
26530401-10	2016	Our findings suggested that hesperetin and naringenin enhanced the systemic exposure of rasagiline might be through the inhibition of CYP1A2 but not P-gp.	rasagiline	88-98	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	134-140
26530401-2	2016	Rasagiline is a selective, monoamine oxidase-B inhibitor and it undergoes significant FPM in the liver prior to excretion by CYP1A2.	rasagiline	0-10	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	125-131
28635937-0	2016	[A role of the MAO-B inhibitor rasagiline in treatment of Parkinson"s disease].	rasagiline	31-41	monoamine oxidase B	Homo sapiens	15-20
28635937-4	2016	Rasagiline (azilect), a new generation MAO-B inhibitor, helps to solve the problems at different stages of PD.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	39-44
28635937-4	2016	Rasagiline (azilect), a new generation MAO-B inhibitor, helps to solve the problems at different stages of PD.	rasagiline	12-19	monoamine oxidase B	Homo sapiens	39-44
26770414-1	2015	Rasagiline, a novel monoamine oxidase (MAO)-B inhibitor, has a mild to moderate effect in relieving Parkinson"s disease (PD) symptoms as well as unique neuroprotective effects.	rasagiline	0-10	monoamine oxidase B	Mus musculus	20-45
26770414-5	2015	A further increase of BAG2 and BAG5 was detected after intragastric administration of rasagiline to post-MPTP lesioned mice.	rasagiline	86-96	BCL2-associated athanogene 2	Mus musculus	22-26
26770414-5	2015	A further increase of BAG2 and BAG5 was detected after intragastric administration of rasagiline to post-MPTP lesioned mice.	rasagiline	86-96	BCL2-associated athanogene 5	Mus musculus	31-35
26770414-6	2015	Thus, the current study proved the association of BAG family proteins with PD, and suggested the involvement and a positive role of BAG2, BAG5 in the neuroprotection of rasagiline.	rasagiline	169-179	BCL2-associated athanogene 2	Mus musculus	132-136
26770414-6	2015	Thus, the current study proved the association of BAG family proteins with PD, and suggested the involvement and a positive role of BAG2, BAG5 in the neuroprotection of rasagiline.	rasagiline	169-179	BCL2-associated athanogene 5	Mus musculus	138-142
26142126-1	2015	The present study aimed to investigate the protective effects of prolonged treatment with the selective, irreversible monoamine oxidase-B inhibitor, novel anti-parkinsonian drug, rasagiline (Azilect) in aged animals.	rasagiline	179-189	monoamine oxidase B	Mus musculus	118-137
25863936-1	2015	Rasagiline and selegiline, inhibitors of type B monoamine oxidase (MAO-B), protect neurons from cell death in cellular and animal models.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	67-72
25863936-4	2015	In this paper, regulation of the mitochondrial permeability transition pore by rasagiline and selegiline was examined in apoptosis induced by PK11195, a ligand of the outer membrane translocator protein 18 kDa (TSPO) in SH-SY5Y cells.	rasagiline	79-89	translocator protein	Homo sapiens	211-215
26142126-5	2015	Furthermore, we found that rasagiline upregulated expression levels of the synaptic plasticity markers brain-derived neurotrophic factor, tyrosine kinase-B receptor, and synapsin-1, increased Bcl-2 to Bax antiapoptotic ratio and the activity of the antioxidant enzyme, catalase in brain of aged mice.	rasagiline	27-37	synapsin I	Mus musculus	138-180
26142126-1	2015	The present study aimed to investigate the protective effects of prolonged treatment with the selective, irreversible monoamine oxidase-B inhibitor, novel anti-parkinsonian drug, rasagiline (Azilect) in aged animals.	rasagiline	191-198	monoamine oxidase B	Mus musculus	118-137
26142126-3	2015	At this dose of rasagiline, chronic drug administration significantly inhibited monoamine oxidase-B activity and caused an increase in striatal dopamine and serotonin levels, while decreasing their metabolism.	rasagiline	16-26	monoamine oxidase B	Mus musculus	80-99
26142126-5	2015	Furthermore, we found that rasagiline upregulated expression levels of the synaptic plasticity markers brain-derived neurotrophic factor, tyrosine kinase-B receptor, and synapsin-1, increased Bcl-2 to Bax antiapoptotic ratio and the activity of the antioxidant enzyme, catalase in brain of aged mice.	rasagiline	27-37	B cell leukemia/lymphoma 2	Mus musculus	192-197
26142126-5	2015	Furthermore, we found that rasagiline upregulated expression levels of the synaptic plasticity markers brain-derived neurotrophic factor, tyrosine kinase-B receptor, and synapsin-1, increased Bcl-2 to Bax antiapoptotic ratio and the activity of the antioxidant enzyme, catalase in brain of aged mice.	rasagiline	27-37	brain derived neurotrophic factor	Mus musculus	103-136
26142126-5	2015	Furthermore, we found that rasagiline upregulated expression levels of the synaptic plasticity markers brain-derived neurotrophic factor, tyrosine kinase-B receptor, and synapsin-1, increased Bcl-2 to Bax antiapoptotic ratio and the activity of the antioxidant enzyme, catalase in brain of aged mice.	rasagiline	27-37	BCL2-associated X protein	Mus musculus	201-204
26142126-5	2015	Furthermore, we found that rasagiline upregulated expression levels of the synaptic plasticity markers brain-derived neurotrophic factor, tyrosine kinase-B receptor, and synapsin-1, increased Bcl-2 to Bax antiapoptotic ratio and the activity of the antioxidant enzyme, catalase in brain of aged mice.	rasagiline	27-37	catalase	Mus musculus	269-277
25368372-1	2015	OBJECTIVE: The current study examined the efficacy and safety of rasagiline, a selective MAO-B inhibitor, for the treatment of persistent negative symptoms.	rasagiline	65-75	monoamine oxidase B	Homo sapiens	89-94
25514361-0	2015	Rasagiline, a suicide inhibitor of monoamine oxidases, binds reversibly to alpha-synuclein.	rasagiline	0-10	synuclein alpha	Homo sapiens	75-90
25514361-1	2015	Rasagiline (N-propargyl-1-R-aminoindan) and selegiline (1-deprenyl) are MAO-B inhibitors which are used in the treatment of Parkinson"s disease.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	72-77
25514361-2	2015	The binding of rasagiline, selegiline, and their metabolites including 1-aminoindan, 2-aminoindan, and methamphetamine to alpha-synuclein was investigated by nanopore analysis and isothermal titration calorimetry.	rasagiline	15-25	synuclein alpha	Homo sapiens	122-137
25514361-6	2015	Rasagiline can also bind to sites in both the N- and C-terminal regions of alpha-synuclein.	rasagiline	0-10	synuclein alpha	Homo sapiens	75-90
25514361-8	2015	A model is presented in which both rasagiline and R-1-aminoindan bind to alpha-synuclein, forming a loop structure which is less likely to aggregate or form fibrils.	rasagiline	35-45	synuclein alpha	Homo sapiens	73-88
25322951-1	2014	Rasagiline (Azilect( )) is an oral, second-generation, selective, irreversible monoamine oxidase-B (MAO-B) inhibitor approved in the US for the treatment of Parkinson"s disease.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	79-98
25832828-1	2015	Rasagiline, a monoamine oxidase B inhibitor, slowed disease progression in the SOD1 mouse, and in a case series of patients with amyotrophic lateral sclerosis (ALS).	rasagiline	0-10	monoamine oxidase B	Mus musculus	14-33
25832828-1	2015	Rasagiline, a monoamine oxidase B inhibitor, slowed disease progression in the SOD1 mouse, and in a case series of patients with amyotrophic lateral sclerosis (ALS).	rasagiline	0-10	superoxide dismutase 1, soluble	Mus musculus	79-83
25832828-7	2015	Rasagiline changed biomarkers over 12 months, such that the mitochondrial membrane potential increased (JC-1 red/green fluorescent ratio 1.92, p = 0.0001) and apoptosis markers decreased (Bcl-2/Bax ratio 0.24, p < 0.0001).	rasagiline	0-10	BCL2 apoptosis regulator	Homo sapiens	188-193
25832828-7	2015	Rasagiline changed biomarkers over 12 months, such that the mitochondrial membrane potential increased (JC-1 red/green fluorescent ratio 1.92, p = 0.0001) and apoptosis markers decreased (Bcl-2/Bax ratio 0.24, p < 0.0001).	rasagiline	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	194-197
25420207-3	2015	We report the effects of the addition of a monoamine oxidase B inhibitor, rasagiline, to antidepressant treatment in PD.	rasagiline	74-84	monoamine oxidase B	Homo sapiens	43-62
25314256-1	2014	BACKGROUND: The serotonin toxicity syndrome (STS) is a potential risk with concurrent use of the monoamine oxidase type-B inhibitor rasagiline and antidepressants.	rasagiline	132-142	monoamine oxidase B	Homo sapiens	97-121
26364897-1	2015	INTRODUCTION: Rasagiline is a potent, selective, irreversible Monoamine Oxidase-B (MAO-B) inhibitor, developed to prolong the action of dopamine in the brain.	rasagiline	14-24	monoamine oxidase B	Homo sapiens	62-81
26364897-1	2015	INTRODUCTION: Rasagiline is a potent, selective, irreversible Monoamine Oxidase-B (MAO-B) inhibitor, developed to prolong the action of dopamine in the brain.	rasagiline	14-24	monoamine oxidase B	Homo sapiens	83-88
25322951-1	2014	Rasagiline (Azilect( )) is an oral, second-generation, selective, irreversible monoamine oxidase-B (MAO-B) inhibitor approved in the US for the treatment of Parkinson"s disease.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	100-105
25322951-1	2014	Rasagiline (Azilect( )) is an oral, second-generation, selective, irreversible monoamine oxidase-B (MAO-B) inhibitor approved in the US for the treatment of Parkinson"s disease.	rasagiline	12-19	monoamine oxidase B	Homo sapiens	79-98
25322951-1	2014	Rasagiline (Azilect( )) is an oral, second-generation, selective, irreversible monoamine oxidase-B (MAO-B) inhibitor approved in the US for the treatment of Parkinson"s disease.	rasagiline	12-19	monoamine oxidase B	Homo sapiens	100-105
24769350-3	2014	In designing the compounds we focused on the structures of rasagiline and selegiline, two well known MAO-B inhibitors and proposed neuroprotective agents.	rasagiline	59-69	monoamine oxidase B	Homo sapiens	101-106
25196265-1	2014	INTRODUCTION: Oxidative stress reduction via monoamine oxidase-B (MAO-B) inhibition with rasagiline is under investigation to modify the course of Parkinson"s disease (PD) progression.	rasagiline	89-99	monoamine oxidase B	Homo sapiens	45-64
25196265-1	2014	INTRODUCTION: Oxidative stress reduction via monoamine oxidase-B (MAO-B) inhibition with rasagiline is under investigation to modify the course of Parkinson"s disease (PD) progression.	rasagiline	89-99	monoamine oxidase B	Homo sapiens	66-71
25196265-5	2014	There is some recent evidence to suggest rasagiline also has monoamine oxidase-A (MAO-A) inhibiting properties, as well as different clinical and pharmacodynamic properties when compared with selegiline, and clinical benefits when used in combination with a dopamine agonist monotherapy.	rasagiline	41-51	monoamine oxidase A	Homo sapiens	61-80
25196265-5	2014	There is some recent evidence to suggest rasagiline also has monoamine oxidase-A (MAO-A) inhibiting properties, as well as different clinical and pharmacodynamic properties when compared with selegiline, and clinical benefits when used in combination with a dopamine agonist monotherapy.	rasagiline	41-51	monoamine oxidase A	Homo sapiens	82-87
24447649-0	2014	Cardiac safety of rasagiline, a selective monoamine oxidase type B inhibitor for the treatment of Parkinson"s disease: a thorough QT/QTc study.	rasagiline	18-28	monoamine oxidase B	Homo sapiens	42-66
24525144-4	2014	In this magnetic resonance (MR) study we used various techniques to characterize the neuroprotective effects of rasagiline, a selective MAO-B inhibitor.	rasagiline	112-122	monoamine oxidase B	Rattus norvegicus	136-141
24447649-1	2014	AIMS: Rasagiline is a selective, irreversible monoamine oxidase type B inhibitor, developed for the treatment of Parkinson"s disease.	rasagiline	6-16	monoamine oxidase B	Homo sapiens	46-70
24197064-2	2014	TVP1022, a non-MAO inhibitor S-isomer of rasagiline, possesses antioxidative and antiapoptotic activities.	rasagiline	0-7	monoamine oxidase A	Rattus norvegicus	15-18
24055209-3	2014	Rasagiline is a second generation MAO-B I inducing moderate symptomatic and possibly disease modifying benefits with apparently good tolerability and safety profile in PD patients.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	34-39
26000219-1	2014	Rasagiline is a monoamine oxidase type-B inhibitor used as monotherapy or in addition to levodopa in the treatment of Parkinson"s disease.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	16-40
24176882-8	2013	Furthermore, we demonstrated that rasagiline, a monoamine oxidase-B (MAO-B) inhibitor that has been shown to be efficacious for PD, could enhance the dendritic complexity of cultured MSNs.	rasagiline	34-44	monoamine oxidase B	Mus musculus	48-67
24176882-8	2013	Furthermore, we demonstrated that rasagiline, a monoamine oxidase-B (MAO-B) inhibitor that has been shown to be efficacious for PD, could enhance the dendritic complexity of cultured MSNs.	rasagiline	34-44	monoamine oxidase B	Mus musculus	69-74
24190245-2	2013	The aim of this investigation was to determine if the MAO-B inhibitor rasagiline can improve olfaction in PD patients.	rasagiline	70-80	monoamine oxidase B	Homo sapiens	54-59
24012376-1	2013	The objective of this study was to synthesize and evaluate a novel fluorine-18 labeled deuterium substituted analogue of rasagiline (9, [(18)F]fluororasagiline-D2) as a potential PET radioligand for studies of monoamine oxidase B (MAO-B).	rasagiline	121-131	monoamine oxidase B	Homo sapiens	210-229
24012376-1	2013	The objective of this study was to synthesize and evaluate a novel fluorine-18 labeled deuterium substituted analogue of rasagiline (9, [(18)F]fluororasagiline-D2) as a potential PET radioligand for studies of monoamine oxidase B (MAO-B).	rasagiline	121-131	monoamine oxidase B	Homo sapiens	231-236
23634791-1	2013	INTRODUCTION: Rasagiline (Azilect, AGN 1135) is a selective irreversible inhibitor of monoamine oxidase B (MAO-B).	rasagiline	14-24	monoamine oxidase B	Homo sapiens	86-105
23735235-1	2013	Rasagiline (Azilect( )) is a selective and irreversible monoamine oxidase B inhibitor, which is well tolerated, safe, improves motor symptoms, and prevents motor complications in Parkinson"s disease (PD).	rasagiline	0-10	monoamine oxidase B	Homo sapiens	56-75
23735235-1	2013	Rasagiline (Azilect( )) is a selective and irreversible monoamine oxidase B inhibitor, which is well tolerated, safe, improves motor symptoms, and prevents motor complications in Parkinson"s disease (PD).	rasagiline	12-19	monoamine oxidase B	Homo sapiens	56-75
23681678-0	2013	Rasagiline prevents apoptosis induced by PK11195, a ligand of the outer membrane translocator protein (18 kDa), in SH-SY5Y cells through suppression of cytochrome c release from mitochondria.	rasagiline	0-10	cytochrome c, somatic	Homo sapiens	152-164
23681678-5	2013	Rasagiline prevented release of cytochrome c (Cyt-c), and the following caspase 3 activation, ATP depletion and apoptosis, but did not inhibit the mitochondrial membrane potential collapse, in contrast to Bcl-2 overexpression.	rasagiline	0-10	cytochrome c, somatic	Homo sapiens	32-44
23681678-5	2013	Rasagiline prevented release of cytochrome c (Cyt-c), and the following caspase 3 activation, ATP depletion and apoptosis, but did not inhibit the mitochondrial membrane potential collapse, in contrast to Bcl-2 overexpression.	rasagiline	0-10	cytochrome c, somatic	Homo sapiens	46-51
23681678-5	2013	Rasagiline prevented release of cytochrome c (Cyt-c), and the following caspase 3 activation, ATP depletion and apoptosis, but did not inhibit the mitochondrial membrane potential collapse, in contrast to Bcl-2 overexpression.	rasagiline	0-10	caspase 3	Homo sapiens	72-81
23681678-6	2013	Rasagiline stabilized the mitochondrial contact site and suppressed Cyt-c release into cytoplasm, which should be the critical point for the regulation of apoptosis.	rasagiline	0-10	cytochrome c, somatic	Homo sapiens	68-73
23634791-1	2013	INTRODUCTION: Rasagiline (Azilect, AGN 1135) is a selective irreversible inhibitor of monoamine oxidase B (MAO-B).	rasagiline	14-24	monoamine oxidase B	Homo sapiens	107-112
23634791-1	2013	INTRODUCTION: Rasagiline (Azilect, AGN 1135) is a selective irreversible inhibitor of monoamine oxidase B (MAO-B).	rasagiline	26-33	monoamine oxidase B	Homo sapiens	86-105
23634791-1	2013	INTRODUCTION: Rasagiline (Azilect, AGN 1135) is a selective irreversible inhibitor of monoamine oxidase B (MAO-B).	rasagiline	26-33	monoamine oxidase B	Homo sapiens	107-112
23634791-1	2013	INTRODUCTION: Rasagiline (Azilect, AGN 1135) is a selective irreversible inhibitor of monoamine oxidase B (MAO-B).	rasagiline	35-43	monoamine oxidase B	Homo sapiens	86-105
23634791-1	2013	INTRODUCTION: Rasagiline (Azilect, AGN 1135) is a selective irreversible inhibitor of monoamine oxidase B (MAO-B).	rasagiline	35-43	monoamine oxidase B	Homo sapiens	107-112
23634791-11	2013	In conclusion, rasagiline is a well-tolerated MAO-B inhibitor that may help to achieve the desired level of clinical benefit in Parkinson"s disease.	rasagiline	15-25	monoamine oxidase B	Homo sapiens	46-51
22968599-2	2013	MAO-B inhibitors, rasagiline and selegiline [(-)deprenyl], protect neuronal cells by direct intervention in mitochondrial death signaling and induction of pro-survival Bcl-2 and neurotrophic factors.	rasagiline	18-28	monoamine oxidase B	Homo sapiens	0-5
23410524-4	2013	l-Deprenyl and rasagiline, both selective MAO-B inhibitors, are used in the management of Parkinson"s disease, but these drugs may be useful in the treatment of other neurodegenerative disorders given that they demonstrate neuroprotective/neurorescue properties in a wide variety of models in vitro and in vivo.	rasagiline	15-25	monoamine oxidase B	Homo sapiens	42-47
23739004-4	2013	MAO-A mediates the induction of antiapoptotic bcl-2 and mao-a itself by rasagiline, whereas a different mechanism is associated with selegiline.	rasagiline	72-82	monoamine oxidase A	Homo sapiens	0-5
23739004-4	2013	MAO-A mediates the induction of antiapoptotic bcl-2 and mao-a itself by rasagiline, whereas a different mechanism is associated with selegiline.	rasagiline	72-82	BCL2 apoptosis regulator	Homo sapiens	46-51
23739004-4	2013	MAO-A mediates the induction of antiapoptotic bcl-2 and mao-a itself by rasagiline, whereas a different mechanism is associated with selegiline.	rasagiline	72-82	monoamine oxidase A	Homo sapiens	56-61
23739004-5	2013	Rasagiline and selegiline preferentially increase GDNF and BDNF in nonhuman primates and Parkinsonian patients, respectively.	rasagiline	0-10	glial cell derived neurotrophic factor	Homo sapiens	50-54
23739004-5	2013	Rasagiline and selegiline preferentially increase GDNF and BDNF in nonhuman primates and Parkinsonian patients, respectively.	rasagiline	0-10	brain derived neurotrophic factor	Homo sapiens	59-63
23242744-7	2013	The MAO-B inhibition activities of the candidates were compared with the properties of rasagiline which is known to be a selective inhibitor of MAO-B.	rasagiline	87-97	monoamine oxidase B	Homo sapiens	144-149
22968599-3	2013	Recently, type A MAO (MAO-A) was found to mediate the induction of anti-apoptotic Bcl-2 by rasagiline, whereas MAO-A increases in neuronal death and also serves as a target of neurotoxins.	rasagiline	91-101	BCL2 apoptosis regulator	Homo sapiens	82-87
22968599-5	2013	This paper reports that rasagiline and selegiline increased the mRNA, protein and catalytic activity of MAO-A in SH-SY5Y cells.	rasagiline	24-34	monoamine oxidase A	Homo sapiens	104-109
22968599-6	2013	Silencing MAO-A expression with small interfering (si)RNA suppressed rasagiline-dependent MAO-A expression, but MAO-B overexpression in SH-SY5Y cells did not affect, suggesting that MAO-A, not MAO-B, might be associated with MAO-A upregulation.	rasagiline	69-79	monoamine oxidase A	Homo sapiens	10-15
22968599-6	2013	Silencing MAO-A expression with small interfering (si)RNA suppressed rasagiline-dependent MAO-A expression, but MAO-B overexpression in SH-SY5Y cells did not affect, suggesting that MAO-A, not MAO-B, might be associated with MAO-A upregulation.	rasagiline	69-79	monoamine oxidase A	Homo sapiens	90-95
22968599-6	2013	Silencing MAO-A expression with small interfering (si)RNA suppressed rasagiline-dependent MAO-A expression, but MAO-B overexpression in SH-SY5Y cells did not affect, suggesting that MAO-A, not MAO-B, might be associated with MAO-A upregulation.	rasagiline	69-79	monoamine oxidase A	Homo sapiens	90-95
22968599-6	2013	Silencing MAO-A expression with small interfering (si)RNA suppressed rasagiline-dependent MAO-A expression, but MAO-B overexpression in SH-SY5Y cells did not affect, suggesting that MAO-A, not MAO-B, might be associated with MAO-A upregulation.	rasagiline	69-79	monoamine oxidase A	Homo sapiens	90-95
22968599-7	2013	Rasagiline reduced R1, a MAO-A specific repressor, but selegiline did not.	rasagiline	0-10	monoamine oxidase A	Homo sapiens	25-30
22968599-8	2013	Mithramycin-A, an inhibitor of Sp1 binding, and actinomycin-D, a transcriptional inhibitor, reduced the rasagiline-dependent upregulation of MAO-A mRNA, indicating that rasagiline induced MAO-A transcriptionally through R1-Sp1 pathway, whereas selegiline by another non-defined pathway.	rasagiline	104-114	monoamine oxidase A	Homo sapiens	141-146
22968599-8	2013	Mithramycin-A, an inhibitor of Sp1 binding, and actinomycin-D, a transcriptional inhibitor, reduced the rasagiline-dependent upregulation of MAO-A mRNA, indicating that rasagiline induced MAO-A transcriptionally through R1-Sp1 pathway, whereas selegiline by another non-defined pathway.	rasagiline	104-114	monoamine oxidase A	Homo sapiens	188-193
22968599-8	2013	Mithramycin-A, an inhibitor of Sp1 binding, and actinomycin-D, a transcriptional inhibitor, reduced the rasagiline-dependent upregulation of MAO-A mRNA, indicating that rasagiline induced MAO-A transcriptionally through R1-Sp1 pathway, whereas selegiline by another non-defined pathway.	rasagiline	169-179	monoamine oxidase A	Homo sapiens	141-146
22968599-8	2013	Mithramycin-A, an inhibitor of Sp1 binding, and actinomycin-D, a transcriptional inhibitor, reduced the rasagiline-dependent upregulation of MAO-A mRNA, indicating that rasagiline induced MAO-A transcriptionally through R1-Sp1 pathway, whereas selegiline by another non-defined pathway.	rasagiline	169-179	monoamine oxidase A	Homo sapiens	188-193
22968599-2	2013	MAO-B inhibitors, rasagiline and selegiline [(-)deprenyl], protect neuronal cells by direct intervention in mitochondrial death signaling and induction of pro-survival Bcl-2 and neurotrophic factors.	rasagiline	18-28	BCL2 apoptosis regulator	Homo sapiens	168-173
22968599-3	2013	Recently, type A MAO (MAO-A) was found to mediate the induction of anti-apoptotic Bcl-2 by rasagiline, whereas MAO-A increases in neuronal death and also serves as a target of neurotoxins.	rasagiline	91-101	monoamine oxidase A	Homo sapiens	22-27
22982254-6	2013	The selective MAO-B inhibitor rasagiline (0.05 mg/kg s.c. daily for 14 days) did not affect microdialysate dopamine concentration [DA(ec)] in sham-operated rats, but decreased OS(ec) by 30%.	rasagiline	30-40	monoamine oxidase B	Rattus norvegicus	14-19
22982254-12	2013	This data implies that gliosis in our 6-OHDA animals together with inhibition of glial cell MAO-B by rasagiline causes an increase in local levels of dopamine at the presynaptic receptors, and a reduction in dopamine release (and in [DA(ec)]) by presynaptic inhibition.	rasagiline	101-111	monoamine oxidase B	Rattus norvegicus	92-97
22982254-13	2013	Moreover, inhibition of MAO-A or MAO-B reduces the enhanced level of oxidative stress in the lesioned striatum, and while both clorgyline and rasagiline reduced DA oxidative metabolism, rasagiline possesses an additional antioxidant property, not only that resulting from MAO inhibition.	rasagiline	186-196	monoamine oxidase A	Rattus norvegicus	24-29
22982254-13	2013	Moreover, inhibition of MAO-A or MAO-B reduces the enhanced level of oxidative stress in the lesioned striatum, and while both clorgyline and rasagiline reduced DA oxidative metabolism, rasagiline possesses an additional antioxidant property, not only that resulting from MAO inhibition.	rasagiline	186-196	monoamine oxidase A	Rattus norvegicus	24-27
23176073-1	2013	OBJECTIVE: Rasagiline is a second-generation, irreversible MAO-B inhibitor (MAOB-I) previously shown to be efficacious and well-tolerated compared to placebo in the treatment of early Parkinson"s disease (PD).	rasagiline	11-21	monoamine oxidase B	Homo sapiens	59-64
22691758-3	2012	In this review, we focus on recent studies with monoamine oxidase type B inhibitors (selegiline and rasagiline), coenzyme Q10, creatine, and exercise in early Parkinson"s disease.	rasagiline	100-110	monoamine oxidase B	Homo sapiens	48-72
22892822-3	2013	In addition, rasagiline and (-)deprenyl increase the expression of anti-apoptotic Bcl-2 protein family and neurotrophic factors.	rasagiline	13-23	BCL2 apoptosis regulator	Homo sapiens	82-87
22892822-8	2013	Rasagiline and (-)deprenyl induced preferentially GDNF and BDNF in cellular and non-human primate experiments, and (-)deprenyl increased BDNF level in the cerebrospinal fluid of parkinsonian patients.	rasagiline	0-10	glial cell derived neurotrophic factor	Homo sapiens	50-54
22892822-8	2013	Rasagiline and (-)deprenyl induced preferentially GDNF and BDNF in cellular and non-human primate experiments, and (-)deprenyl increased BDNF level in the cerebrospinal fluid of parkinsonian patients.	rasagiline	0-10	brain derived neurotrophic factor	Homo sapiens	59-63
23573275-0	2013	Rasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson"s disease.	rasagiline	0-10	synuclein, alpha	Mus musculus	48-63
23573275-4	2013	Preliminary clinical observations suggest that rasagiline, a monoamine oxidase-B inhibitor, improves olfaction in Parkinson"s disease.	rasagiline	47-57	monoamine oxidase B	Mus musculus	61-80
22954444-1	2012	The objective was to investigate the anodal iontophoresis of the MAO-B inhibitors rasagiline (RAS) and selegiline (SEL) across porcine and human skin in vitro.	rasagiline	82-92	monoamine oxidase B	Homo sapiens	65-70
22954444-1	2012	The objective was to investigate the anodal iontophoresis of the MAO-B inhibitors rasagiline (RAS) and selegiline (SEL) across porcine and human skin in vitro.	rasagiline	94-97	monoamine oxidase B	Homo sapiens	65-70
23346517-5	2012	Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor that has recently been approved by the Food and Drug Administration for treatment of Parkinson"s disease.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	48-72
23346517-5	2012	Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor that has recently been approved by the Food and Drug Administration for treatment of Parkinson"s disease.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	74-79
23410161-6	2013	The design strategy for yet another agent, ladostigil, employed the amalgamation of active chemical moieties of the AChE inhibitor rivastigmine, and the monoamine oxidase-B (MAO-B) inhibitor rasagiline, leading to a single compound that targets both enzymes simultaneously.	rasagiline	191-201	monoamine oxidase B	Homo sapiens	153-172
23410161-6	2013	The design strategy for yet another agent, ladostigil, employed the amalgamation of active chemical moieties of the AChE inhibitor rivastigmine, and the monoamine oxidase-B (MAO-B) inhibitor rasagiline, leading to a single compound that targets both enzymes simultaneously.	rasagiline	191-201	monoamine oxidase B	Homo sapiens	174-179
22426424-1	2012	Based on a multimodal drug design paradigm, we have synthesized a multifunctional non-toxic, brain permeable iron chelating compound, M30, possessing the neuroprotective N-propargyl moiety of the anti-Parkinsonian drug, monoamine oxidase (MAO)-B inhibitor, rasagiline and the antioxidant-iron chelator moiety of an 8-hydroxyquinoline derivative of the iron chelator, VK28.	rasagiline	257-267	olfactory receptor family 10 subfamily N member 1	Mus musculus	134-137
21628600-0	2012	The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?	rasagiline	39-49	monoamine oxidase B	Homo sapiens	4-28
21628600-1	2012	Rasagiline is an irreversible monoamine oxidase type B (MAO-B) inhibitor indicated for the treatment of the signs and symptoms of idiopathic Parkinson disease as initial monotherapy and as adjunct therapy to levodopa.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	30-54
21628600-1	2012	Rasagiline is an irreversible monoamine oxidase type B (MAO-B) inhibitor indicated for the treatment of the signs and symptoms of idiopathic Parkinson disease as initial monotherapy and as adjunct therapy to levodopa.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	56-61
21628600-3	2012	Tyramine challenge studies, conducted to characterize rasagiline selectivity for the MAO-B enzyme and tyramine sensitivity, demonstrate that rasagiline, when used at the recommended dose, is selective for MAO-B and is not associated with heightened tyramine sensitivity.	rasagiline	54-64	monoamine oxidase B	Homo sapiens	85-90
21628600-3	2012	Tyramine challenge studies, conducted to characterize rasagiline selectivity for the MAO-B enzyme and tyramine sensitivity, demonstrate that rasagiline, when used at the recommended dose, is selective for MAO-B and is not associated with heightened tyramine sensitivity.	rasagiline	141-151	monoamine oxidase B	Homo sapiens	85-90
21628600-3	2012	Tyramine challenge studies, conducted to characterize rasagiline selectivity for the MAO-B enzyme and tyramine sensitivity, demonstrate that rasagiline, when used at the recommended dose, is selective for MAO-B and is not associated with heightened tyramine sensitivity.	rasagiline	141-151	monoamine oxidase B	Homo sapiens	205-210
21628600-6	2012	In addition, because rasagiline has been demonstrated to be selective for MAO-B at the approved dose of up to 1 mg/d, contraindications regarding concomitant use with sympathomimetic amines, use of sympathomimetic vasopressors in conjunction with general or local anesthesia, and use in patients with pheochromocytoma also were removed.	rasagiline	21-31	monoamine oxidase B	Homo sapiens	74-79
22436387-1	2012	The aim of this study was to synthesize and evaluate a novel fluorine-18 labeled analogue of rasagiline (6) as a PET radioligand for monoamine oxidase B (MAO-B).	rasagiline	93-103	monoamine oxidase B	Homo sapiens	133-152
22436387-1	2012	The aim of this study was to synthesize and evaluate a novel fluorine-18 labeled analogue of rasagiline (6) as a PET radioligand for monoamine oxidase B (MAO-B).	rasagiline	93-103	monoamine oxidase B	Homo sapiens	154-159
22436387-7	2012	Blocking experiments with pirlindole (MAO-A), L-deprenyl and rasagiline (MAO-B) were conducted to demonstrate the specificity of the binding.	rasagiline	61-71	monoamine oxidase B	Homo sapiens	73-78
22439669-1	2012	Rasagiline (Azilect ), a selective, irreversible, monoamine oxidase-B inhibitor, is available in the EU, the US and in several other countries worldwide, including Canada and Israel.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	50-69
22065207-0	2012	Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase.	rasagiline	82-92	BCL2 apoptosis regulator	Homo sapiens	73-78
22065207-1	2012	Rasagiline and (-)deprenyl (selegiline), irreversible type B monoamine oxidase (MAO-B) inhibitors, protect neuronal cells through gene induction of pro-survival Bcl-2 and neurotrophic factors in the cellular models of neurodegenerative disorders.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	80-85
22065207-1	2012	Rasagiline and (-)deprenyl (selegiline), irreversible type B monoamine oxidase (MAO-B) inhibitors, protect neuronal cells through gene induction of pro-survival Bcl-2 and neurotrophic factors in the cellular models of neurodegenerative disorders.	rasagiline	0-10	BCL2 apoptosis regulator	Homo sapiens	161-166
22065207-3	2012	Rasagiline and (-)deprenyl, and also befloxatone, a reversible MAO-A inhibitor, increased Bcl-2 mRNA and protein in SH-SY5Y cells.	rasagiline	0-10	BCL2 apoptosis regulator	Homo sapiens	90-95
22065207-4	2012	Silencing MAO-A expression with short interfering (si) RNA suppressed Bcl-2 induction by rasagiline, but not by (-)deprenyl.	rasagiline	89-99	monoamine oxidase A	Homo sapiens	10-15
22065207-4	2012	Silencing MAO-A expression with short interfering (si) RNA suppressed Bcl-2 induction by rasagiline, but not by (-)deprenyl.	rasagiline	89-99	BCL2 apoptosis regulator	Homo sapiens	70-75
22065207-5	2012	MAO-B overexpression inhibited Bcl-2 induction by rasagiline and befloxatone, but did not affect that by (-)deprenyl, suggesting the different mechanisms behind Bcl-2 gene induction by these MAO-B inhibitors.	rasagiline	50-60	monoamine oxidase B	Homo sapiens	0-5
22065207-5	2012	MAO-B overexpression inhibited Bcl-2 induction by rasagiline and befloxatone, but did not affect that by (-)deprenyl, suggesting the different mechanisms behind Bcl-2 gene induction by these MAO-B inhibitors.	rasagiline	50-60	BCL2 apoptosis regulator	Homo sapiens	31-36
22065207-6	2012	The novel role of MAO-A in Bcl-2 induction by rasagiline is discussed with regard to the molecular mechanism underlying neuroprotection by the MAO inhibitors.	rasagiline	46-56	monoamine oxidase A	Homo sapiens	18-23
22065207-6	2012	The novel role of MAO-A in Bcl-2 induction by rasagiline is discussed with regard to the molecular mechanism underlying neuroprotection by the MAO inhibitors.	rasagiline	46-56	BCL2 apoptosis regulator	Homo sapiens	27-32
22065207-6	2012	The novel role of MAO-A in Bcl-2 induction by rasagiline is discussed with regard to the molecular mechanism underlying neuroprotection by the MAO inhibitors.	rasagiline	46-56	monoamine oxidase A	Homo sapiens	18-21
22439669-1	2012	Rasagiline (Azilect ), a selective, irreversible, monoamine oxidase-B inhibitor, is available in the EU, the US and in several other countries worldwide, including Canada and Israel.	rasagiline	12-19	monoamine oxidase B	Homo sapiens	50-69
23030609-0	2012	QSAR and molecular docking techniques for the discovery of potent monoamine oxidase B inhibitors: computer-aided generation of new rasagiline bioisosteres.	rasagiline	131-141	monoamine oxidase B	Homo sapiens	66-85
21878836-0	2012	Rasagiline interferes with neurodegeneration in the Prph2/rds mouse.	rasagiline	0-10	peripherin 2	Mus musculus	52-57
21878836-0	2012	Rasagiline interferes with neurodegeneration in the Prph2/rds mouse.	rasagiline	0-10	peripherin 2	Mus musculus	58-61
21878836-9	2012	CONCLUSION: This study showed for the first time significant neuroprotective effects of rasagiline in the retina of Prph2/rds mice through caspase-dependent pathways.	rasagiline	88-98	peripherin 2	Mus musculus	116-121
21878836-9	2012	CONCLUSION: This study showed for the first time significant neuroprotective effects of rasagiline in the retina of Prph2/rds mice through caspase-dependent pathways.	rasagiline	88-98	peripherin 2	Mus musculus	122-125
21819487-1	2012	BACKGROUND: Rasagiline, an MAO-B inhibitor, is indicated for the treatment of Parkinson"s disease (PD).	rasagiline	12-22	monoamine oxidase B	Homo sapiens	27-32
23030609-6	2012	We also give a brief overview about one of the most potent MAO-B inhibitor drugs: rasagiline.	rasagiline	82-92	monoamine oxidase B	Homo sapiens	59-64
23030609-8	2012	By realizing a careful inspection of the meaning of the variables in the QSAR-ANN model, new rasagiline bioisosteres were suggested as possible potent MAO-B inhibitors.	rasagiline	93-103	monoamine oxidase B	Homo sapiens	151-156
23231395-4	2012	On the other hand, deprenyl and rasagiline, selective MAO-B inhibitors, have been proved to protect neuronal cells in cellular and animal models of neurodegeneration.	rasagiline	32-42	monoamine oxidase B	Homo sapiens	54-59
23030618-0	2012	3D MI-DRAGON: new model for the reconstruction of US FDA drug- target network and theoretical-experimental studies of inhibitors of rasagiline derivatives for AChE.	rasagiline	132-142	acetylcholinesterase (Cartwright blood group)	Homo sapiens	159-163
23030618-17	2012	First, we have reported the prediction and pharmacological assay of 22 different rasagiline derivatives with possible AChE inhibitory activity.	rasagiline	81-91	acetylcholinesterase (Cartwright blood group)	Homo sapiens	118-122
21360301-3	2011	Although Moussa Youdim succeeded in exploring the novel anti-Parkinsonian, selective MAO-B inhibitor drug, rasagiline (Azilect, Teva Pharmaceutical Co.), he did not stop searching for superior therapeutic approaches for neurodegenerative disorders.	rasagiline	107-117	monoamine oxidase B	Homo sapiens	85-90
22045282-1	2011	OBJECTIVE: Rasagiline, a monoamine oxidase type B inhibitor, is indicated for both the initial treatment of Parkinson disease (PD) and as adjunctive (add-on) treatment for patients already taking dopaminergic therapy.	rasagiline	11-21	monoamine oxidase B	Homo sapiens	25-49
22087552-8	2011	It appears that early treatment with the MAO-B inhibitor rasagiline (1 mg), as compared with late treatment, delays the onset of worsened UPDRS score, especially the nonmotor activities of daily living subscore.	rasagiline	57-67	monoamine oxidase B	Homo sapiens	41-46
21939547-4	2011	DISCUSSION: In multiple studies, MAO-B inhibitors, such as selegiline and rasagiline, have shown to provide mild symptomatic effects, delay the need for levodopa, and to reduce the incidence of motor fluctuations.	rasagiline	74-84	monoamine oxidase B	Homo sapiens	33-38
21500280-2	2011	Rasagiline is a selective monoamine oxidase type-B inhibitor that enhances central dopaminergic transmission.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	26-50
21500280-13	2011	The monoamine oxidase type-B inhibitor rasagiline may exert beneficial effects on certain aspects of attention and executive functions in nondemented patients with Parkinson"s disease with cognitive impairment.	rasagiline	39-49	monoamine oxidase B	Homo sapiens	4-28
21812497-12	2011	Of the three delayed-start design clinical trials, two have investigated early versus later start of rasagiline, a specific irreversible monoamine oxidase B inhibitor.	rasagiline	101-111	monoamine oxidase B	Homo sapiens	137-156
25205926-5	2011	Other pharmacological measures like catechol-O-methyltrasferase (COMT) inhibitors like entacopone, telcapone and monoamine oxidase B (MAO-B) inhibitors like selegiline and rasagiline are also useful, while L-dopa remains the gold standard in the treatment of PD.	rasagiline	172-182	catechol-O-methyltransferase	Homo sapiens	36-63
22110357-4	2011	For the treatment of akinesia and motor fluctuations selective irreversible MAO-B inhibitors selegiline and rasagiline are recommended.	rasagiline	108-118	monoamine oxidase B	Homo sapiens	76-81
22133327-4	2011	Two MAO-B inhibitors, selegiline and rasagiline, are currently licensed in Europe and North America for the symptomatic improvement of early Parkinson"s disease and to reduce off-time in patients with more advanced Parkinson"s disease and motor fluctuations related to levodopa.	rasagiline	37-47	monoamine oxidase B	Homo sapiens	4-9
21946113-5	2011	In hippocampus as well as in striatum, rasagiline induces a significant reduction of synaptic levels of NR2A-containing NMDA receptors and in hippocampal slices it also significantly decreases synaptic levels of GluR1-containing AMPA receptors.	rasagiline	39-49	glutamate ionotropic receptor AMPA type subunit 1	Homo sapiens	212-217
21953831-5	2011	Monoamine oxidase B (MAO-B) located in the outer mitochondrial membrane controls dopamine metabolism in early PD, and this is the likely location for the symptomatic action of rasagiline.	rasagiline	176-186	monoamine oxidase B	Homo sapiens	0-19
21953831-5	2011	Monoamine oxidase B (MAO-B) located in the outer mitochondrial membrane controls dopamine metabolism in early PD, and this is the likely location for the symptomatic action of rasagiline.	rasagiline	176-186	monoamine oxidase B	Homo sapiens	21-26
21953831-8	2011	Thus, the functional neuroprotective actions of rasagiline may not be dependent on MAO-B inhibition, but rather may involve actions of the propargylamine moiety and the aminoindan metabolite.	rasagiline	48-58	monoamine oxidase B	Homo sapiens	83-88
21626552-5	2011	Novel dopamine agonists (pramipexole, ropinirole, rotigotine), catecholmethyltransferase inhibitors (entacapone), and monoamine oxidase B inhibitors (rasagiline) have also been developed to provide more continuous oral delivery of dopaminergic stimulation in order to improve motor outcomes.	rasagiline	150-160	monoamine oxidase B	Homo sapiens	118-137
20919927-1	2011	The anti-Parkinsonian, monoamine oxidase-B inhibitor drug, rasagiline (Azilect ), is primarily metabolized by hepatic cytochrome P450 isoenzyme 1A2-mediated N-dealkylation to form its major metabolite, 1-(R)-aminoindan.	rasagiline	59-69	monoamine oxidase B	Rattus norvegicus	23-42
20919927-1	2011	The anti-Parkinsonian, monoamine oxidase-B inhibitor drug, rasagiline (Azilect ), is primarily metabolized by hepatic cytochrome P450 isoenzyme 1A2-mediated N-dealkylation to form its major metabolite, 1-(R)-aminoindan.	rasagiline	71-78	monoamine oxidase B	Rattus norvegicus	23-42
21971007-2	2011	The MAO-B inhibitor rasagiline has neuroprotective effects in animal models, mediated partly by its antiapoptotic activity.	rasagiline	20-30	monoamine oxidase B	Homo sapiens	4-9
21338509-1	2011	BACKGROUND: Rasagiline, a new drug developed to treat Parkinson"s disease, is known to inhibit monoamine oxidase B.	rasagiline	12-22	monoamine oxidase B	Rattus norvegicus	95-114
21423589-4	2011	This review focuses on rasagiline and selegiline, two medications that belong to a class of antiparkinsonian drugs called monoamine oxidase B (MAO-B) inhibitors.	rasagiline	23-33	monoamine oxidase B	Homo sapiens	122-141
21423589-4	2011	This review focuses on rasagiline and selegiline, two medications that belong to a class of antiparkinsonian drugs called monoamine oxidase B (MAO-B) inhibitors.	rasagiline	23-33	monoamine oxidase B	Homo sapiens	143-148
21971006-2	2011	Rasagiline (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible MAO-B inhibitor in the treatment of Parkinson"s disease (PD).	rasagiline	0-10	monoamine oxidase B	Homo sapiens	81-86
21075154-10	2011	Deprenyl itself as well as the MAO-B antagonist rasagiline did effectively block the binding of the radioligand, whereas the MAO-A antagonist pirlindole did not affect it.	rasagiline	48-58	monoamine oxidase B	Homo sapiens	31-36
21947069-1	2011	The features of the new selective MAO-B inhibitor razagiline (azilect) are reviewed against the background of latest advances in the field of treatment of Parkinson"s disease (PD).	rasagiline	62-69	monoamine oxidase B	Homo sapiens	34-39
20600573-0	2010	Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	38-57
20445015-0	2010	Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline.	rasagiline	126-136	monoamine oxidase B	Homo sapiens	83-107
20445015-0	2010	Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline.	rasagiline	126-136	monoamine oxidase B	Homo sapiens	109-114
20445015-1	2010	Rasagiline is a selective, monoamine oxidase (MAO)-B inhibitor indicated for treatment of Parkinson"s disease.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	27-52
20445015-9	2010	Results demonstrate that rasagiline selectively inhibits MAO-B and is not associated with increased tyramine sensitivity at the indicated dose (1 mg/d).	rasagiline	25-35	monoamine oxidase B	Homo sapiens	57-62
20624440-0	2010	Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells.	rasagiline	0-10	synuclein alpha	Homo sapiens	28-43
20624440-1	2010	Rasagiline is a propargylamine and irreversible monoamine oxidase (MAO) B inhibitor used for the treatment of Parkinson"s disease (PD).	rasagiline	0-10	monoamine oxidase B	Homo sapiens	48-73
20624440-5	2010	We demonstrate that rasagiline protects against cell death induced by the combination of free radicals generated by paraquat and either wild-type or A53T mutant alpha-synuclein over-expression.	rasagiline	20-30	synuclein alpha	Homo sapiens	161-176
20624440-8	2010	The results support a role for rasagiline in protecting dopaminergic cells against free radical mediated damage and apoptosis in the presence of alpha-synuclein over-expression.	rasagiline	31-41	synuclein alpha	Homo sapiens	145-160
20600573-1	2010	Rasagiline (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO)-B inhibitor, anti-Parkinsonian drug.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	81-106
20600573-3	2010	Its S-isomer, TVP1022 is thousand times less potent as an MAO-B inhibitor.	rasagiline	14-21	monoamine oxidase B	Homo sapiens	58-63
20600573-4	2010	However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of rasagiline does not depend on inhibition of MAO-B, but rather is associated with the N-propargyl moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating Bcl-2 family proteins.	rasagiline	186-196	monoamine oxidase B	Homo sapiens	230-235
20979033-4	2010	DEVELOPMENT: Rasagiline is a monoamine oxidase-B inhibitor whose dopaminergic stimulation has proved to be effective in monotherapy or in combined therapy for improving the motor symptoms in patients with PD in the initial and advanced phases.	rasagiline	13-23	monoamine oxidase B	Homo sapiens	29-48
20236308-1	2010	BACKGROUND: The MAO-B inhibitor rasagiline is indicated for the treatment of idiopathic Parkinson"s disease (PD), and its use is supported by evidence from large-scale, controlled clinical studies.	rasagiline	32-42	monoamine oxidase B	Homo sapiens	16-21
23908775-0	2010	Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson"s Disease with Neuroprotective Potential.	rasagiline	16-26	monoamine oxidase B	Homo sapiens	34-39
23908775-1	2010	Rasagiline (Azilect) is a highly selective and potent propargylamine inhibitor of monoamine oxidase (MAO) type B.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	82-112
23908775-1	2010	Rasagiline (Azilect) is a highly selective and potent propargylamine inhibitor of monoamine oxidase (MAO) type B.	rasagiline	12-19	monoamine oxidase B	Homo sapiens	82-112
23908775-7	2010	Following subchronic administration to normal rats, rasagiline increases levels of dopamine in striatal microdialysate, possibly by the build-up of beta-phenylethylamine, which is an excellent substrate for MAO-B, and is an effective inhibitor of the plasma membrane dopamine transporter (DAT).	rasagiline	52-62	monoamine oxidase B	Rattus norvegicus	207-212
23908775-7	2010	Following subchronic administration to normal rats, rasagiline increases levels of dopamine in striatal microdialysate, possibly by the build-up of beta-phenylethylamine, which is an excellent substrate for MAO-B, and is an effective inhibitor of the plasma membrane dopamine transporter (DAT).	rasagiline	52-62	solute carrier family 6 member 3	Rattus norvegicus	267-287
23908775-7	2010	Following subchronic administration to normal rats, rasagiline increases levels of dopamine in striatal microdialysate, possibly by the build-up of beta-phenylethylamine, which is an excellent substrate for MAO-B, and is an effective inhibitor of the plasma membrane dopamine transporter (DAT).	rasagiline	52-62	solute carrier family 6 member 3	Rattus norvegicus	289-292
20022592-10	2010	Knockdown expression of GAPDH or treatment with MAO B inhibitors selegiline (deprenyl) and rasagiline (Azilect) can block this cascade.	rasagiline	91-101	glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens	24-29
20517484-3	2010	Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor which has been approved for treatment of PD.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	48-72
20517484-3	2010	Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor which has been approved for treatment of PD.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	74-79
20517484-4	2010	Rasagiline inhibits MAO-B more potently than selegiline and has the advantage of once-daily dosing.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	20-25
20022592-10	2010	Knockdown expression of GAPDH or treatment with MAO B inhibitors selegiline (deprenyl) and rasagiline (Azilect) can block this cascade.	rasagiline	91-101	monoamine oxidase B	Homo sapiens	48-53
20022592-10	2010	Knockdown expression of GAPDH or treatment with MAO B inhibitors selegiline (deprenyl) and rasagiline (Azilect) can block this cascade.	rasagiline	103-110	glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens	24-29
20022592-10	2010	Knockdown expression of GAPDH or treatment with MAO B inhibitors selegiline (deprenyl) and rasagiline (Azilect) can block this cascade.	rasagiline	103-110	monoamine oxidase B	Homo sapiens	48-53
20002521-1	2010	The anti-parkinsonian drug, rasagiline [N-propargyl-1-(R)-aminoindan; Azilect(R)], is a secondary cyclic benzylamine and indane derivative, which provides irreversible, potent monoamine oxidase-B (MAO-B) inhibition and possesses neuroprotective and neurorestorative activities.	rasagiline	28-38	monoamine oxidase B	Homo sapiens	176-195
20195940-3	2010	The MAO B inhibitors selegiline and rasagiline are in use for PD pharmacotherapy; for rasagiline, studies have demonstrated a possible disease-modifying effect.	rasagiline	36-46	monoamine oxidase B	Homo sapiens	4-9
20002521-1	2010	The anti-parkinsonian drug, rasagiline [N-propargyl-1-(R)-aminoindan; Azilect(R)], is a secondary cyclic benzylamine and indane derivative, which provides irreversible, potent monoamine oxidase-B (MAO-B) inhibition and possesses neuroprotective and neurorestorative activities.	rasagiline	28-38	monoamine oxidase B	Homo sapiens	197-202
20002521-3	2010	Rasagiline is primarily metabolized by hepatic cytochrome P-450 to form its major metabolite, 1-(R)-aminoindan, a non-amphetamine, weak reversible MAO-B inhibitor compound.	rasagiline	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-63
20002521-3	2010	Rasagiline is primarily metabolized by hepatic cytochrome P-450 to form its major metabolite, 1-(R)-aminoindan, a non-amphetamine, weak reversible MAO-B inhibitor compound.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	147-152
19110207-5	2009	This review discusses the multimodal effects of two rasagiline-containing hybrid molecules, namely ladostigil and M-30, concerning their neuroprotective molecular mechanisms in vivo and in vitro, including regulation of amyloid precursor protein processing, activation of protein kinase C, and mitogen-activated protein kinase signaling pathways, inhibition of cell death markers and upregulation of neurotrophic factors.	rasagiline	52-62	amyloid beta precursor protein	Homo sapiens	220-245
20698822-7	2010	In cellular models, selegiline and rasagiline increased the different neurotrophic factors classes, neurotrophins (nerve growth factor, brain-derive neurotrophic factor, neurotrophin 3) and ligands of glial cell line-derived neurotrophic factor, respectively.	rasagiline	35-45	glial cell derived neurotrophic factor	Homo sapiens	201-244
20609912-4	2010	This NO-dependent cell signaling pathway of the redox protein Trx may play a key role in the cellular protective mechanism of several potential neuroprotective agents such as S-nitrosoglutathione (GSNO), 17beta-estradiol, selegiline as well as ebeselen, sildenafil, and rasagiline.	rasagiline	270-280	thioredoxin	Homo sapiens	62-65
20714170-1	2010	BACKGROUND: Rasagiline and selegiline are classified as monoamine oxidase B (MAO-B) inhibitors.	rasagiline	12-22	monoamine oxidase B	Rattus norvegicus	56-75
20714170-1	2010	BACKGROUND: Rasagiline and selegiline are classified as monoamine oxidase B (MAO-B) inhibitors.	rasagiline	12-22	monoamine oxidase B	Rattus norvegicus	77-82
19733607-5	2009	The MAO-A-dependent catecholamine metabolite DHPG levels did not change significantly during the study suggesting that rasagiline"s MAO-B selectivity was preserved.	rasagiline	119-129	monoamine oxidase A	Homo sapiens	4-9
19733607-5	2009	The MAO-A-dependent catecholamine metabolite DHPG levels did not change significantly during the study suggesting that rasagiline"s MAO-B selectivity was preserved.	rasagiline	119-129	monoamine oxidase B	Homo sapiens	132-137
19763773-5	2009	Rasagiline and (-)deprenyl, type B MAO inhibitors of propagylamine-derivatives, bind to MAO-A to protect neuronal cells against apoptosis through induction of pro-survival Bcl-2 and neurotrophic factors.	rasagiline	0-10	monoamine oxidase A	Homo sapiens	88-93
19763773-5	2009	Rasagiline and (-)deprenyl, type B MAO inhibitors of propagylamine-derivatives, bind to MAO-A to protect neuronal cells against apoptosis through induction of pro-survival Bcl-2 and neurotrophic factors.	rasagiline	0-10	BCL2 apoptosis regulator	Homo sapiens	172-177
19110207-2	2009	Ladostigil combines, in a single molecule, the neuroprotective/neurorestorative effects of the novel anti-Parkinsonian drug and selective monoamine oxidase (MAO)-B inhibitor, rasagiline (Azilect, Teva Pharmaceutical Co.) with the cholinesterase (ChE) inhibitory activity of rivastigmine.	rasagiline	175-185	monoamine oxidase B	Homo sapiens	138-163
20977789-1	2010	Rasagiline is a MAO-B inhibitor that is currently registered for the symptomatic treatment of Parkinson disease.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	16-21
20197647-1	2010	BACKGROUND: The anti-Parkinson monoamine oxidase B inhibitor rasagiline appears to be the first neuroprotective disease-modifying therapy in early-stage Parkinson"s disease (PD).	rasagiline	61-71	monoamine oxidase B	Homo sapiens	31-50
20197647-4	2010	A detailed analysis revealed a complementary action of these drugs, differentially acting at MPTP-injured molecules/targets in the substantia nigra (SN): induction of brain-derived neurotrophic factor by rasagiline, increased membranal levels of the protein kinase C alpha-isoform by EGCG and a synergistic replenishment of their downstream effector, the serine/threonine kinase Akt/protein kinase B, suggesting that this kinase might represent one point of convergence of the distinct mechanisms of action of the drug cocktail.	rasagiline	204-214	brain derived neurotrophic factor	Homo sapiens	167-200
21389939-1	2010	An open observational 3-month study of efficacy and safety of selective MAO B inhibitor rasagiline (AZIlect) in advanced Parkinson"s disease (PD) patients with motor fluctuations on the long-term levodopa therapy (the "AZIMUT" study) has been conducted.	rasagiline	88-98	monoamine oxidase B	Homo sapiens	72-77
21389939-1	2010	An open observational 3-month study of efficacy and safety of selective MAO B inhibitor rasagiline (AZIlect) in advanced Parkinson"s disease (PD) patients with motor fluctuations on the long-term levodopa therapy (the "AZIMUT" study) has been conducted.	rasagiline	100-107	monoamine oxidase B	Homo sapiens	72-77
19396396-1	2009	The novel anti-Parkinson"s disease (PD) drug, rasagiline (N-propargyl-1-(R)-aminoindan), is a second generation of irreversible selective inhibitor of monoamine oxidase-B follows selegiline.	rasagiline	46-56	monoamine oxidase B	Rattus norvegicus	151-170
19673610-5	2009	Rasagiline-related MAOB-Is prevent mitochondrial permeability transition induced by various insults and activation of subsequent apoptotic cascades: cytochrome c release, casapase activation, and condensation and fragmentation of nuclear DNA.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	19-23
19673610-5	2009	Rasagiline-related MAOB-Is prevent mitochondrial permeability transition induced by various insults and activation of subsequent apoptotic cascades: cytochrome c release, casapase activation, and condensation and fragmentation of nuclear DNA.	rasagiline	0-10	cytochrome c, somatic	Homo sapiens	149-161
19673610-7	2009	Rasagiline increases the protein and mRNA levels of GDNF in dopaminergic SH-SY5Y cells, whereas (-)deprenyl increases those of BDNF.	rasagiline	0-10	glial cell derived neurotrophic factor	Homo sapiens	52-56
19526291-0	2009	Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan.	rasagiline	116-126	glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens	0-40
19526291-0	2009	Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan.	rasagiline	116-126	monoamine oxidase B	Homo sapiens	41-60
19526291-6	2009	In contrast, the MAO B inhibitors rasagiline and selegiline (0.25 nM) and the rasagiline metabolite, 1-R-aminoindan (1 muM) decreases the ethanol-induced MAO B, prevents nuclear translocation of GAPDH and reduces cell death.	rasagiline	34-44	monoamine oxidase B	Homo sapiens	17-22
19526291-6	2009	In contrast, the MAO B inhibitors rasagiline and selegiline (0.25 nM) and the rasagiline metabolite, 1-R-aminoindan (1 muM) decreases the ethanol-induced MAO B, prevents nuclear translocation of GAPDH and reduces cell death.	rasagiline	34-44	monoamine oxidase B	Homo sapiens	154-159
19526291-6	2009	In contrast, the MAO B inhibitors rasagiline and selegiline (0.25 nM) and the rasagiline metabolite, 1-R-aminoindan (1 muM) decreases the ethanol-induced MAO B, prevents nuclear translocation of GAPDH and reduces cell death.	rasagiline	78-88	latexin	Homo sapiens	119-122
19526291-6	2009	In contrast, the MAO B inhibitors rasagiline and selegiline (0.25 nM) and the rasagiline metabolite, 1-R-aminoindan (1 muM) decreases the ethanol-induced MAO B, prevents nuclear translocation of GAPDH and reduces cell death.	rasagiline	78-88	monoamine oxidase B	Homo sapiens	154-159
19526291-6	2009	In contrast, the MAO B inhibitors rasagiline and selegiline (0.25 nM) and the rasagiline metabolite, 1-R-aminoindan (1 muM) decreases the ethanol-induced MAO B, prevents nuclear translocation of GAPDH and reduces cell death.	rasagiline	78-88	glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens	195-200
19526291-10	2009	Thus, the neuroprotective effects of rasagiline or 1-R-aminoindan on ethanol-induced cell death mediated by a novel GAPDH-MAO B pathway may provide a new insight in the treatment of neurobiological diseases including alcohol-use disorders.	rasagiline	37-47	glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens	116-121
19526291-10	2009	Thus, the neuroprotective effects of rasagiline or 1-R-aminoindan on ethanol-induced cell death mediated by a novel GAPDH-MAO B pathway may provide a new insight in the treatment of neurobiological diseases including alcohol-use disorders.	rasagiline	37-47	monoamine oxidase B	Homo sapiens	122-127
19753135-1	2009	Rasagiline is a second generation, selective, irreversible monoamine oxidase type B (MAO-B) inhibitor.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	59-83
19753135-1	2009	Rasagiline is a second generation, selective, irreversible monoamine oxidase type B (MAO-B) inhibitor.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	85-90
19384601-10	2009	Rasagiline exhibited highest inhibition on MAO B enzymatic activity and prevention on DNA damage as compared to selegiline and 1-R-aminoindan.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	43-48
19499843-1	2009	Rasagiline (RSG) and selegiline (SEL) are potent selective monoamine oxidase-B inhibitors and used in the treatment of Parkinson"s disease.	rasagiline	0-10	amine oxidase [flavin-containing] B	Oryctolagus cuniculus	59-78
19499843-1	2009	Rasagiline (RSG) and selegiline (SEL) are potent selective monoamine oxidase-B inhibitors and used in the treatment of Parkinson"s disease.	rasagiline	12-15	amine oxidase [flavin-containing] B	Oryctolagus cuniculus	59-78
18678789-0	2008	Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease.	rasagiline	80-90	monoamine oxidase B	Homo sapiens	50-69
18952510-1	2008	Rasagiline is a highly potent, selective and irreversible second-generation monoamine oxidase inhibitor with selectivity for type B of the enzyme (MAO-B).	rasagiline	0-10	monoamine oxidase B	Homo sapiens	147-152
18833504-2	2008	Rasagiline (Azilect) is a potent, highly selective and irreversible inhibitor of monoamine oxidase type B of the second generation.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	81-105
18833504-2	2008	Rasagiline (Azilect) is a potent, highly selective and irreversible inhibitor of monoamine oxidase type B of the second generation.	rasagiline	12-19	monoamine oxidase B	Homo sapiens	81-105
18937611-1	2008	BACKGROUND: The role of monoamine oxidase type B inhibitors in the treatment of Parkinson"s disease has expanded with the new monoamine oxidase B inhibitor rasagiline and a new formulation, selegiline oral disintegrating tablets.	rasagiline	156-166	monoamine oxidase B	Homo sapiens	24-48
18937611-9	2008	The recently released monoamine oxidase B inhibitor rasagiline and a new formulation, selegiline oral disintegrating tablets, have potential advantages over conventional oral selegiline.	rasagiline	52-62	monoamine oxidase B	Homo sapiens	22-41
18806903-1	2008	Rasagiline, a selective COMT inhibitor, and rotigotine, a transdermal dopamine (D2) agonist, are two new agents that have been approved in the U.S. and Europe for the treatment of Parkinson"s disease.	rasagiline	0-10	catechol-O-methyltransferase	Homo sapiens	24-28
18806608-4	2008	We demonstrated that pretreatment of NRVM cultures with TVP1022 or propargylamine attenuated doxorubicin-induced and serum starvation-induced apoptosis, inhibited the increase in cleaved caspase 3 levels, and reversed the decline in Bcl-2/Bax ratio.	rasagiline	56-63	BCL2, apoptosis regulator	Rattus norvegicus	233-238
18806608-4	2008	We demonstrated that pretreatment of NRVM cultures with TVP1022 or propargylamine attenuated doxorubicin-induced and serum starvation-induced apoptosis, inhibited the increase in cleaved caspase 3 levels, and reversed the decline in Bcl-2/Bax ratio.	rasagiline	56-63	BCL2 associated X, apoptosis regulator	Rattus norvegicus	239-242
18307054-1	2008	Rasagiline is a selective and irreversible monoamine oxidase-B inhibitor.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	43-62
18399960-3	2008	Rasagiline and selegiline are selective and irreversible monoamine oxidase-B inhibitors that possess significant protective properties on dopamine neurons in various pre-clinical models of PD.	rasagiline	0-10	monoamine oxidase B	Mus musculus	57-76
18771016-2	2008	In 2007 the desmethyl-analogue of J-508 (rasagiline) was registered as a new selective inhibitor of MAO-B and a possible substitute for (-)-deprenyl in therapy.	rasagiline	41-51	monoamine oxidase B	Rattus norvegicus	100-105
18222424-1	2008	Rasagiline is a novel selective irreversible monoamine oxidase-B (MAO-B) inhibitor recently introduced for the symptomatic treatment of Parkinson disease.	rasagiline	0-10	monoamine oxidase B	Mus musculus	45-64
18222424-1	2008	Rasagiline is a novel selective irreversible monoamine oxidase-B (MAO-B) inhibitor recently introduced for the symptomatic treatment of Parkinson disease.	rasagiline	0-10	monoamine oxidase B	Mus musculus	66-71
18072817-1	2008	Rasagiline (Azilect) is a novel, selective, irreversible second-generation inhibitor of monoamine oxidase type B (MAO-B).	rasagiline	0-10	monoamine oxidase B	Homo sapiens	88-112
18067186-3	2008	Treatment with the new irreversible monoamine oxidase B inhibitor rasagiline at standard doses resulted in a rapid, dramatic, and sustained improvement of the frequency and duration of FOG episodes.	rasagiline	66-76	monoamine oxidase B	Homo sapiens	36-55
18067186-3	2008	Treatment with the new irreversible monoamine oxidase B inhibitor rasagiline at standard doses resulted in a rapid, dramatic, and sustained improvement of the frequency and duration of FOG episodes.	rasagiline	66-76	zinc finger protein, FOG family member 1	Homo sapiens	185-188
18072817-1	2008	Rasagiline (Azilect) is a novel, selective, irreversible second-generation inhibitor of monoamine oxidase type B (MAO-B).	rasagiline	0-10	monoamine oxidase B	Homo sapiens	114-119
18072817-1	2008	Rasagiline (Azilect) is a novel, selective, irreversible second-generation inhibitor of monoamine oxidase type B (MAO-B).	rasagiline	12-19	monoamine oxidase B	Homo sapiens	88-112
18072817-1	2008	Rasagiline (Azilect) is a novel, selective, irreversible second-generation inhibitor of monoamine oxidase type B (MAO-B).	rasagiline	12-19	monoamine oxidase B	Homo sapiens	114-119
19004128-0	2008	[The use of a new MAO B inhibitor rasagiline in the treatment of motor fluctuations in Parkinson"s disease].	rasagiline	34-44	monoamine oxidase B	Homo sapiens	18-23
18668620-8	2008	MAO-B inhibitors (selegiline and rasagiline) can decrease FOG frequency or severity, but its clinical significance is still unknown.	rasagiline	33-43	monoamine oxidase B	Homo sapiens	0-5
18668620-8	2008	MAO-B inhibitors (selegiline and rasagiline) can decrease FOG frequency or severity, but its clinical significance is still unknown.	rasagiline	33-43	zinc finger protein, FOG family member 1	Homo sapiens	58-61
17823767-0	2008	Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline.	rasagiline	122-132	monoamine oxidase A	Rattus norvegicus	107-110
18041937-3	2007	The two available MAO-B inhibitors approved for use in the United States, rasagiline and selegiline, each provide symptomatic relief as monotherapy and as adjunctive therapy, and have shown potential disease-modifying effects in experimental models and clinical studies.	rasagiline	74-84	monoamine oxidase B	Homo sapiens	18-23
18077571-0	2007	Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy.	rasagiline	103-113	glial cell derived neurotrophic factor	Homo sapiens	34-38
18077571-0	2007	Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy.	rasagiline	103-113	brain derived neurotrophic factor	Homo sapiens	43-47
18077571-5	2007	We have recently reported that the anti-PD drug rasagiline, the anti-AD drug ladostigil, and their propargyl moiety, propargylamine, enhanced the expression levels of brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor, endogenous NTFs associated with activation of phosphatidylinositol 3-kinase, protein kinase, and mitogen-activated protein kinase cell signaling/survival pathways.	rasagiline	48-58	brain derived neurotrophic factor	Homo sapiens	167-200
18077571-5	2007	We have recently reported that the anti-PD drug rasagiline, the anti-AD drug ladostigil, and their propargyl moiety, propargylamine, enhanced the expression levels of brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor, endogenous NTFs associated with activation of phosphatidylinositol 3-kinase, protein kinase, and mitogen-activated protein kinase cell signaling/survival pathways.	rasagiline	48-58	glial cell derived neurotrophic factor	Homo sapiens	205-248
18035186-2	2007	Rasagiline [N-propargyl-l(R)-aminoindan] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain MAO-B and is specifically designed for the treatment of Parkinson"s disease (PD).	rasagiline	0-10	monoamine oxidase B	Homo sapiens	142-147
17635668-1	2007	The anti-Parkinson, selective irreversible monoamine oxidase B inhibitor drug, rasagiline (Azilect), recently approved by the US Food and Drug Administration, has been shown to possess neuroprotective-neurorescue activities in in vitro and in vivo models.	rasagiline	79-89	monoamine oxidase B	Homo sapiens	43-62
17635668-1	2007	The anti-Parkinson, selective irreversible monoamine oxidase B inhibitor drug, rasagiline (Azilect), recently approved by the US Food and Drug Administration, has been shown to possess neuroprotective-neurorescue activities in in vitro and in vivo models.	rasagiline	91-98	monoamine oxidase B	Homo sapiens	43-62
18035186-8	2007	Based on the results from those studies, we concluded that rasagiline PO QD, at the therapeutic dosage range of 0.5 to 1 rag/d, is effective and well tolerated and completely, selectively, and specifically inhibited MAO-B.	rasagiline	59-69	monoamine oxidase B	Homo sapiens	216-221
17347320-2	2007	It was postulated that certain carbamate esters would inhibit AChE and BChE with the concomitant release in the brain of the OH-derivatives of rasagiline or selegiline that can serve as inhibitors of MAO-B and as antioxidants.	rasagiline	143-153	monoamine oxidase B	Homo sapiens	200-205
17545750-3	2007	Data have been reported regarding the selective MAO-B inhibitors, rasagiline and selegiline, for the symptomatic treatment of Parkinson disease (PD).	rasagiline	66-76	monoamine oxidase B	Homo sapiens	48-53
18488080-0	2007	Rasagiline - a novel MAO B inhibitor in Parkinson"s disease therapy.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	21-26
18488080-3	2007	Recently, a novel selective and irreversible MAO B propargylamine inhibitor rasagiline (N-propargyl-1-R-aminoindan, Azilect((R))) was approved for PD therapy.	rasagiline	76-86	monoamine oxidase B	Homo sapiens	45-50
18488080-3	2007	Recently, a novel selective and irreversible MAO B propargylamine inhibitor rasagiline (N-propargyl-1-R-aminoindan, Azilect((R))) was approved for PD therapy.	rasagiline	116-123	monoamine oxidase B	Homo sapiens	45-50
18488080-6	2007	Rasagiline undergoes extensive hepatic metabolism primarily by cytochrome P450 type 1A2 (CYP1A2).	rasagiline	0-10	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	63-87
18488080-6	2007	Rasagiline undergoes extensive hepatic metabolism primarily by cytochrome P450 type 1A2 (CYP1A2).	rasagiline	0-10	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	89-95
17545750-7	2007	Rasagiline is a selective, second-generation, irreversible MAO-B inhibitor, with at least 5 times the potency of selegiline in vitro and in animal models.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	59-64
17982885-5	2007	At the same time, rasagiline induces anti-apoptotic pro-survival proteins, Bcl-2 and glial cell-line derived neurotrophic factor, which is mediated by activated ERK-NF-kappaB signal pathway.	rasagiline	18-28	glial cell derived neurotrophic factor	Homo sapiens	85-128
17630819-5	2007	Agents that block MAO-B, such as rasagiline and selegiline, are used as both initial and adjunctive therapy in patients with Parkinson"s disease.	rasagiline	33-43	monoamine oxidase B	Homo sapiens	18-23
17982885-5	2007	At the same time, rasagiline induces anti-apoptotic pro-survival proteins, Bcl-2 and glial cell-line derived neurotrophic factor, which is mediated by activated ERK-NF-kappaB signal pathway.	rasagiline	18-28	BCL2 apoptosis regulator	Homo sapiens	75-80
17495756-4	2007	Although no medication has been proven to slow the progression of Parkinson disease, preclinical studies have demonstrated neuroprotective effects of MAO-B inhibitors, and a recent study of rasagiline found that PD patients treated with rasagiline for 12 months experienced less progression of symptoms than patients treated with placebo for 6 months followed by rasagiline for 6 months.	rasagiline	237-247	monoamine oxidase B	Homo sapiens	150-155
17495756-4	2007	Although no medication has been proven to slow the progression of Parkinson disease, preclinical studies have demonstrated neuroprotective effects of MAO-B inhibitors, and a recent study of rasagiline found that PD patients treated with rasagiline for 12 months experienced less progression of symptoms than patients treated with placebo for 6 months followed by rasagiline for 6 months.	rasagiline	237-247	monoamine oxidase B	Homo sapiens	150-155
17683172-1	2007	Rasagiline (Azilect) is a novel, selective, irreversible second-generation inhibitor of monoamine oxidase type B (MAO-B).	rasagiline	0-10	monoamine oxidase B	Homo sapiens	88-112
17683172-1	2007	Rasagiline (Azilect) is a novel, selective, irreversible second-generation inhibitor of monoamine oxidase type B (MAO-B).	rasagiline	0-10	monoamine oxidase B	Homo sapiens	114-119
17683172-1	2007	Rasagiline (Azilect) is a novel, selective, irreversible second-generation inhibitor of monoamine oxidase type B (MAO-B).	rasagiline	12-19	monoamine oxidase B	Homo sapiens	88-112
17683172-1	2007	Rasagiline (Azilect) is a novel, selective, irreversible second-generation inhibitor of monoamine oxidase type B (MAO-B).	rasagiline	12-19	monoamine oxidase B	Homo sapiens	114-119
17702535-10	2007	Rasagiline is a new, selective, second-generation MAO-B inhibitor that is chemically and metabolically distinct from selegiline.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	50-55
17982885-5	2007	At the same time, rasagiline induces anti-apoptotic pro-survival proteins, Bcl-2 and glial cell-line derived neurotrophic factor, which is mediated by activated ERK-NF-kappaB signal pathway.	rasagiline	18-28	nuclear factor kappa B subunit 1	Homo sapiens	165-174
17157368-7	2006	Morphine reinforcement was also decreased by each of the three active treatments, but greater and more prolonged effects were observed following inhibition of MAO-B with rasagiline.	rasagiline	170-180	monoamine oxidase B	Rattus norvegicus	159-164
18267281-5	2007	MAO-B inhibitors rasagiline or selegiline can be also added.	rasagiline	17-27	monoamine oxidase B	Homo sapiens	0-5
17055733-1	2007	The anti-Parkinson monoamine oxidase (MAO)-B inhibitor rasagiline (Azilect) was shown to possess neuroprotective activities, involving the induction of brain-derived- and glial cell line-derived neurotrophic factors (BDNF, GDNF).	rasagiline	55-65	monoamine oxidase B	Homo sapiens	19-44
17055733-1	2007	The anti-Parkinson monoamine oxidase (MAO)-B inhibitor rasagiline (Azilect) was shown to possess neuroprotective activities, involving the induction of brain-derived- and glial cell line-derived neurotrophic factors (BDNF, GDNF).	rasagiline	55-65	brain derived neurotrophic factor	Homo sapiens	217-221
17055733-1	2007	The anti-Parkinson monoamine oxidase (MAO)-B inhibitor rasagiline (Azilect) was shown to possess neuroprotective activities, involving the induction of brain-derived- and glial cell line-derived neurotrophic factors (BDNF, GDNF).	rasagiline	55-65	glial cell derived neurotrophic factor	Homo sapiens	223-227
17055733-1	2007	The anti-Parkinson monoamine oxidase (MAO)-B inhibitor rasagiline (Azilect) was shown to possess neuroprotective activities, involving the induction of brain-derived- and glial cell line-derived neurotrophic factors (BDNF, GDNF).	rasagiline	67-74	monoamine oxidase B	Homo sapiens	19-44
17055733-1	2007	The anti-Parkinson monoamine oxidase (MAO)-B inhibitor rasagiline (Azilect) was shown to possess neuroprotective activities, involving the induction of brain-derived- and glial cell line-derived neurotrophic factors (BDNF, GDNF).	rasagiline	67-74	brain derived neurotrophic factor	Homo sapiens	217-221
17055733-1	2007	The anti-Parkinson monoamine oxidase (MAO)-B inhibitor rasagiline (Azilect) was shown to possess neuroprotective activities, involving the induction of brain-derived- and glial cell line-derived neurotrophic factors (BDNF, GDNF).	rasagiline	67-74	glial cell derived neurotrophic factor	Homo sapiens	223-227
17055733-3	2007	Rasagiline induced the activation of cell signaling mediators associated with neurotrophic factors responsive-tyrosine kinase receptor (Trk) pathway including ShcC, SOS, AF6, Rin1 and Ras and the increase in the Trk-downstream effector phosphatidylinositol 3 kinase (PI3K) protein.	rasagiline	0-10	neurotrophic receptor tyrosine kinase 1	Homo sapiens	99-134
17055733-3	2007	Rasagiline induced the activation of cell signaling mediators associated with neurotrophic factors responsive-tyrosine kinase receptor (Trk) pathway including ShcC, SOS, AF6, Rin1 and Ras and the increase in the Trk-downstream effector phosphatidylinositol 3 kinase (PI3K) protein.	rasagiline	0-10	neurotrophic receptor tyrosine kinase 1	Homo sapiens	136-139
17055733-3	2007	Rasagiline induced the activation of cell signaling mediators associated with neurotrophic factors responsive-tyrosine kinase receptor (Trk) pathway including ShcC, SOS, AF6, Rin1 and Ras and the increase in the Trk-downstream effector phosphatidylinositol 3 kinase (PI3K) protein.	rasagiline	0-10	afadin, adherens junction formation factor	Homo sapiens	170-173
17055733-3	2007	Rasagiline induced the activation of cell signaling mediators associated with neurotrophic factors responsive-tyrosine kinase receptor (Trk) pathway including ShcC, SOS, AF6, Rin1 and Ras and the increase in the Trk-downstream effector phosphatidylinositol 3 kinase (PI3K) protein.	rasagiline	0-10	Ras and Rab interactor 1	Homo sapiens	175-179
17055733-3	2007	Rasagiline induced the activation of cell signaling mediators associated with neurotrophic factors responsive-tyrosine kinase receptor (Trk) pathway including ShcC, SOS, AF6, Rin1 and Ras and the increase in the Trk-downstream effector phosphatidylinositol 3 kinase (PI3K) protein.	rasagiline	0-10	neurotrophic receptor tyrosine kinase 1	Homo sapiens	212-215
17055733-3	2007	Rasagiline induced the activation of cell signaling mediators associated with neurotrophic factors responsive-tyrosine kinase receptor (Trk) pathway including ShcC, SOS, AF6, Rin1 and Ras and the increase in the Trk-downstream effector phosphatidylinositol 3 kinase (PI3K) protein.	rasagiline	0-10	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	236-265
17055733-5	2007	Thus, the activation of Ras-PI3K-Akt survival pathway may contribute to rasagiline-mediated neurorescue effect.	rasagiline	72-82	AKT serine/threonine kinase 1	Homo sapiens	33-36
17296539-7	2006	Rasagiline is almost completely eliminated by oxidative metabolism (catalyzed by cytochrome P-450 [CYP] isozyme 1A2) followed by renal excretion of conjugated parent compound and metabolites.	rasagiline	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-115
17296539-12	2006	CYP1A2 inhibitors slow the elimination of rasagiline and mandate dosage reduction.	rasagiline	42-52	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	0-6
17296539-18	2006	In addition, bifunctional molecules combining selective MAO-B inhibition (based on the active moiety of rasagiline) with acetylcholinesterase inhibition or iron chelation may eventually be useful in Alzheimer"s disease.	rasagiline	104-114	monoamine oxidase B	Homo sapiens	56-61
17016505-2	2006	Rasagiline is a new, potent and selective MAO-B inhibitor, which does not possess the sympathomimetic effects of selegiline.	rasagiline	0-10	monoamine oxidase B	Rattus norvegicus	42-47
16828804-2	2006	Rasagiline (N-propargyl-1(R)-aminoindan) mesylate is a novel, second-generation, selective, irreversible monoamine oxidase type B inhibitor, demonstrated in monotherapy and adjunctive trials to be effective for PD with excellent tolerability.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	105-129
16450340-2	2006	Rasagiline, a potent, second-generation, irreversible, selective monoamine oxidase B inhibitor improves PD symptoms in patients with early PD.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	65-84
16935943-2	2006	Ladostigil combines the neuroprotective effects of the antiparkinson drug rasagiline, a selective monoamine oxidase (MAO)-B inhibitor, with the cholinesterase (ChE) inhibitory activity of rivastigmine in a single molecule, as a potential treatment for Alzheimer"s disease (AD) and Lewy Body disease.	rasagiline	74-84	monoamine oxidase B	Homo sapiens	98-123
16856145-0	2006	Effects of tyramine administration in Parkinson"s disease patients treated with selective MAO-B inhibitor rasagiline.	rasagiline	106-116	monoamine oxidase B	Homo sapiens	90-95
16856145-1	2006	Rasagiline is a novel, potent, and selective MAO-B inhibitor shown to be effective for Parkinson"s disease.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	45-50
16675649-0	2006	Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson"s disease.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	32-56
16675649-2	2006	SUMMARY: Rasagiline is a novel, investigational propargylamine that irreversibly and selectively inhibits monoamine oxidase type B (MAO-B).	rasagiline	9-19	monoamine oxidase B	Homo sapiens	106-130
16675649-2	2006	SUMMARY: Rasagiline is a novel, investigational propargylamine that irreversibly and selectively inhibits monoamine oxidase type B (MAO-B).	rasagiline	9-19	monoamine oxidase B	Homo sapiens	132-137
16675649-3	2006	Rasagiline demonstrates complete and selective inhibition of MAO-B and is at least five times more potent than selegiline.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	61-66
16675649-12	2006	CONCLUSION: Rasagiline is an investigational selective and irreversible inhibitor of MAO-B that has demonstrated efficacy and safety for the treatment of PD.	rasagiline	12-22	monoamine oxidase B	Homo sapiens	85-90
16717254-7	2006	Rasagiline is another MAO-B inhibitor that contains a propargyl ring and has protective effects in laboratory models.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	22-27
16717255-1	2006	Rasagiline (N-propargyl-1 (R)-aminoindan) is a selective, potent irreversible inhibitor of MAO-B that possesses neuroprotective and anti-apoptotic properties in a variety of in vitro and in vivo animal models relevant to Parkinson"s disease (PD).	rasagiline	0-10	monoamine oxidase B	Homo sapiens	91-96
20104716-4	2006	For young patients, dopamine-agonists and, indeed, once again increasingly MAO-B inhibitors, such as rasagiline, are mainly used for therapy.	rasagiline	101-111	monoamine oxidase B	Homo sapiens	75-80
17447416-7	2006	MAO B inhibitors such as L-(-)-deprenyl (selegiline) and rasagiline are effective for the treatment of PD.	rasagiline	57-67	monoamine oxidase B	Homo sapiens	0-5
16425668-4	2006	The methyl-esterified form of L-DOPA (melevodopa) and the monoamine oxidase type B inhibitor rasagiline have both been launched.	rasagiline	93-103	monoamine oxidase B	Homo sapiens	58-82
17017568-1	2006	Our recent studies aimed to elucidate the molecular and biochemical mechanism of actions of the novel anti-Parkinson"s drug, rasagiline, an irreversible and selective monoamine oxidase (MAO)-B inhibitor and its propargyl moiety, propargylamine.	rasagiline	125-135	monoamine oxidase B	Homo sapiens	167-192
17017568-3	2006	Rasagiline and propargylamine inhibited the cleavage and subsequent activation of pro-caspase-3 and poly ADP-ribose polymerase.	rasagiline	0-10	caspase 3	Homo sapiens	82-95
16451296-4	2006	Rasagiline is a novel, second-generation, irreversible, selective monoamine oxidase type B inhibitor that is indicated for the treatment of idiopathic PD, either as initial monotherapy or as adjunct therapy (with levodopa) for patients experiencing end-of-dose motor fluctuations.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	66-90
17447417-10	2006	Rasagiline and other MAO-B inhibitors prevent the activation of apoptotic cascade and induce prosurvival genes, such as bcl-2 and glial cell line-derived neurotrophic factor, in MAO-A-containing cells.	rasagiline	0-10	BCL2 apoptosis regulator	Homo sapiens	120-125
17447417-10	2006	Rasagiline and other MAO-B inhibitors prevent the activation of apoptotic cascade and induce prosurvival genes, such as bcl-2 and glial cell line-derived neurotrophic factor, in MAO-A-containing cells.	rasagiline	0-10	glial cell derived neurotrophic factor	Homo sapiens	130-173
16197359-2	2005	Rasagiline is a monoamine oxidase-B inhibitor that has demonstrated efficacy against the cardinal symptoms of Parkinson"s disease when used as monotherapy in early Parkinson"s disease, and as an adjunct to levodopa in advanced disease stages.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	16-35
17447417-10	2006	Rasagiline and other MAO-B inhibitors prevent the activation of apoptotic cascade and induce prosurvival genes, such as bcl-2 and glial cell line-derived neurotrophic factor, in MAO-A-containing cells.	rasagiline	0-10	monoamine oxidase A	Homo sapiens	178-183
16148027-9	2005	These results indicate that both rasagiline and propargylamine possess neurorescue activity, associated with regulation of Bcl-2 family proteins, neurotrophic factors, and APP metabolism.	rasagiline	33-43	BCL2 apoptosis regulator	Homo sapiens	123-128
17017568-3	2006	Rasagiline and propargylamine inhibited the cleavage and subsequent activation of pro-caspase-3 and poly ADP-ribose polymerase.	rasagiline	0-10	poly(ADP-ribose) polymerase 1	Homo sapiens	100-126
17017568-5	2006	Rasagiline and propargylamine both regulated amyloid precursor protein (APP) processing towards the non-amyloidogenic pathway.	rasagiline	0-10	amyloid beta precursor protein	Homo sapiens	45-70
16366596-2	2005	Rasagiline is an irreversible, MAO B-selective inhibitor that has been approved as a novel anti-Parkinson"s drug.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	31-36
16366596-3	2005	In this study, we investigate the inhibition of recombinant human MAO A and MAO B by several rasagiline analogues.	rasagiline	93-103	monoamine oxidase A	Homo sapiens	66-71
16366596-3	2005	In this study, we investigate the inhibition of recombinant human MAO A and MAO B by several rasagiline analogues.	rasagiline	93-103	monoamine oxidase B	Homo sapiens	76-81
16366596-6	2005	The 1.7 A crystal structure of MAO B in complex with 4-(N-methyl-N-ethyl-carbamoyloxy)-N-methyl-N-propargyl-1(R)-aminoindan shows that the binding mode is similar to that of rasagiline with the carbamate moiety occupying the entrance cavity space.	rasagiline	174-184	monoamine oxidase B	Homo sapiens	31-36
16366596-7	2005	1(R)-Aminoindan, the major metabolic product of rasagiline, and its analogues reversibly inhibit both MAO A and MAO B.	rasagiline	48-58	monoamine oxidase A	Homo sapiens	102-107
16366596-7	2005	1(R)-Aminoindan, the major metabolic product of rasagiline, and its analogues reversibly inhibit both MAO A and MAO B.	rasagiline	48-58	monoamine oxidase B	Homo sapiens	112-117
16366596-8	2005	The crystal structure of N-methyl-1(R)-aminoindan bound to MAO B shows that its aminoindan ring adopts a different orientation compared to that of rasagiline.	rasagiline	147-157	monoamine oxidase B	Homo sapiens	59-64
16274338-8	2005	Clinical data suggest, in addition, a disease-modifying effect of rasagiline that may correlate with neuroprotective activity of monoamine oxidase-B inhibitors in animal models of Parkinson"s disease.	rasagiline	66-76	monoamine oxidase B	Homo sapiens	129-148
16204711-0	2005	In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET.	rasagiline	62-72	monoamine oxidase B	Homo sapiens	29-48
16204711-3	2005	In this study, we used (11)C-l-deprenyl PET to demonstrate the specific binding characteristics of the new irreversible selective MAO-B inhibitor rasagiline in 3 healthy volunteers.	rasagiline	146-156	monoamine oxidase B	Homo sapiens	130-135
16204711-6	2005	The areas of high uptake were absent from scan 2, on which activity throughout the brain was comparable to that in white matter, presumably because of blocking of MAO-B binding sites by rasagiline.	rasagiline	186-196	monoamine oxidase B	Homo sapiens	163-168
16110345-0	2005	Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline.	rasagiline	134-144	monoamine oxidase B	Homo sapiens	95-100
16204711-8	2005	CONCLUSION: (11)C-l-deprenyl PET showed binding of rasagiline to MAO-B, confirming blocking of MAO-B sites after 10 d of treatment with 1 mg of rasagiline per day, with immediate post-rasagiline treatment tracer uptake and metabolism in the basal ganglia compatible only with nonspecific binding.	rasagiline	51-61	monoamine oxidase B	Homo sapiens	65-70
16204711-8	2005	CONCLUSION: (11)C-l-deprenyl PET showed binding of rasagiline to MAO-B, confirming blocking of MAO-B sites after 10 d of treatment with 1 mg of rasagiline per day, with immediate post-rasagiline treatment tracer uptake and metabolism in the basal ganglia compatible only with nonspecific binding.	rasagiline	144-154	monoamine oxidase B	Homo sapiens	95-100
16204711-8	2005	CONCLUSION: (11)C-l-deprenyl PET showed binding of rasagiline to MAO-B, confirming blocking of MAO-B sites after 10 d of treatment with 1 mg of rasagiline per day, with immediate post-rasagiline treatment tracer uptake and metabolism in the basal ganglia compatible only with nonspecific binding.	rasagiline	144-154	monoamine oxidase B	Homo sapiens	95-100
16204711-10	2005	This finding is compatible with the known rate of de novo synthesis of MAO-B, confirming the irreversible binding of rasagiline.	rasagiline	117-127	monoamine oxidase B	Homo sapiens	71-76
16179541-0	2005	Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway.	rasagiline	45-55	BCL2, apoptosis regulator	Rattus norvegicus	112-117
16179541-0	2005	Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway.	rasagiline	45-55	protein kinase C, gamma	Rattus norvegicus	138-141
16179541-1	2005	Our studies have provided new insights into the biological mechanism of neuroprotection of the anti-Parkinson drug, rasagiline [N-propargyl-(1R)-aminoindan], involving the association of Bcl-2 family proteins with protein kinase C (PKC) pathway.	rasagiline	116-126	BCL2, apoptosis regulator	Rattus norvegicus	187-192
16179541-1	2005	Our studies have provided new insights into the biological mechanism of neuroprotection of the anti-Parkinson drug, rasagiline [N-propargyl-(1R)-aminoindan], involving the association of Bcl-2 family proteins with protein kinase C (PKC) pathway.	rasagiline	116-126	protein kinase C, gamma	Rattus norvegicus	232-235
16179541-4	2005	In addition, rasagiline decreased serum-free-induced levels of the important regulator of cell death, Bad, which was also blocked by GF109203X, indicating the involvement of PKC-dependent cell survival activity of rasagiline.	rasagiline	13-23	protein kinase C, gamma	Rattus norvegicus	174-177
16179541-4	2005	In addition, rasagiline decreased serum-free-induced levels of the important regulator of cell death, Bad, which was also blocked by GF109203X, indicating the involvement of PKC-dependent cell survival activity of rasagiline.	rasagiline	214-224	protein kinase C, gamma	Rattus norvegicus	174-177
16027398-1	2005	Rasagiline is a novel second-generation propargylamine that irreversibly and selectively inhibits monoamine oxidase type B (MAO-B).	rasagiline	0-10	monoamine oxidase B	Homo sapiens	98-122
16027398-1	2005	Rasagiline is a novel second-generation propargylamine that irreversibly and selectively inhibits monoamine oxidase type B (MAO-B).	rasagiline	0-10	monoamine oxidase B	Homo sapiens	124-129
16027398-3	2005	Rasagiline completely and selectively inhibits MAO-B with a potency 5 to 10 times greater than selegiline.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	47-52
15765264-0	2005	Neuroprotective effect of rasagiline, a monoamine oxidase-B inhibitor, on spontaneous cell degeneration in a rat model.	rasagiline	26-36	monoamine oxidase B	Rattus norvegicus	40-59
16007239-2	2005	The search for pharmacological treatments able to counteract the nigrostriatal degeneration, possibly by interfering with these phenomena, has recently raised considerable interest in rasagiline [R(+)-N-propargyl-1-aminoindan], a potent, selective, and irreversible inhibitor of monoamine oxidase B (MAO-B).	rasagiline	184-194	monoamine oxidase B	Homo sapiens	279-298
16007239-2	2005	The search for pharmacological treatments able to counteract the nigrostriatal degeneration, possibly by interfering with these phenomena, has recently raised considerable interest in rasagiline [R(+)-N-propargyl-1-aminoindan], a potent, selective, and irreversible inhibitor of monoamine oxidase B (MAO-B).	rasagiline	184-194	monoamine oxidase B	Homo sapiens	300-305
16110345-1	2005	Rasagiline (N-propargyl-1R-aminoindan) is a novel, highly potent, irreversible monoamine oxidase (MAO)-B inhibitor designed for use as an antiparkinsonian drug.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	79-104
15721173-1	2005	Rasagiline (N-propargyl-1-R-aminoindan) is a new selective inhibitor of MAO-B which is in development for the treatment of Parkinson"s disease.	rasagiline	0-10	monoamine oxidase B	Rattus norvegicus	72-77
15850677-3	2005	Rasagiline (N-propargyl-1R-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO) B inhibitor, anti-Parkinson drug.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	78-103
15850677-10	2005	Structure activity studies have shown that the neuroprotective activity is associated with the propargyl moiety of rasagiline which protects mitochondrial viability and MPTp by activating Bcl-2 and protein kinase C (PKC), and down regulating pro-apoptotic FAS and Bax.	rasagiline	115-125	BCL2 apoptosis regulator	Homo sapiens	188-193
15850677-10	2005	Structure activity studies have shown that the neuroprotective activity is associated with the propargyl moiety of rasagiline which protects mitochondrial viability and MPTp by activating Bcl-2 and protein kinase C (PKC), and down regulating pro-apoptotic FAS and Bax.	rasagiline	115-125	BCL2 associated X, apoptosis regulator	Homo sapiens	264-267
15621213-0	2005	Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.	rasagiline	49-59	monoamine oxidase B	Homo sapiens	33-38
15710852-1	2005	BACKGROUND: Rasagiline (n-propargyl-1[R]-aminoindan) mesylate is a novel irreversible selective monoamine oxidase type B inhibitor, previously demonstrated to improve symptoms in early Parkinson disease (PD).	rasagiline	12-22	monoamine oxidase B	Homo sapiens	96-120
15621213-7	2005	We have therefore prepared a series of novel bifunctional drugs from the neuroprotective-antiapoptotic antiparkinson monoamine oxidase B inhibitor, rasagiline, by introducing a carbamate cholinesterase (ChE) inhibitory moiety into it.	rasagiline	148-158	monoamine oxidase B	Homo sapiens	117-136
15621213-7	2005	We have therefore prepared a series of novel bifunctional drugs from the neuroprotective-antiapoptotic antiparkinson monoamine oxidase B inhibitor, rasagiline, by introducing a carbamate cholinesterase (ChE) inhibitory moiety into it.	rasagiline	148-158	butyrylcholinesterase	Homo sapiens	187-201
15621213-7	2005	We have therefore prepared a series of novel bifunctional drugs from the neuroprotective-antiapoptotic antiparkinson monoamine oxidase B inhibitor, rasagiline, by introducing a carbamate cholinesterase (ChE) inhibitory moiety into it.	rasagiline	148-158	butyrylcholinesterase	Homo sapiens	203-206
15573406-3	2005	Rasagiline (N-propargyl-1R-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO) B inhibitor anti-Parkinson drug.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	78-103
15663351-1	2005	Rasagiline is a second-generation potent, irreversible and selective inhibitor of monoamine-oxidase type B (MAO-B), which has been evaluated for the treatment of Parkinson"s disease.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	82-106
15663351-1	2005	Rasagiline is a second-generation potent, irreversible and selective inhibitor of monoamine-oxidase type B (MAO-B), which has been evaluated for the treatment of Parkinson"s disease.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	108-113
16156677-10	2005	Rasagiline is a new MAO-B inhibitor that is not broken down to amphetamine derivatives and is indicated as both monotherapy in early PD and as adjunctive therapy in PD patients with motor fluctuations.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	20-25
15573406-12	2005	The identification of the propargylamine moiety as the neuroprotective component of rasagiline has led us to development of novel bifunctional anti-Alzheimer drugs (ladostigil) possessing cholinesterase and brain-selective MAO inhibitory activity and a similar neuroprotective mechanism of action.	rasagiline	84-94	butyrylcholinesterase	Homo sapiens	188-202
15628826-13	2004	CONCLUSION: Rasagiline is well tolerated at doses up to 20 mg once/day and is a potent inhibitor of platelet MAO-B in humans.	rasagiline	12-22	monoamine oxidase B	Homo sapiens	109-114
15339864-0	2004	Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline.	rasagiline	27-37	monoamine oxidase B	Rattus norvegicus	89-108
15339864-15	2004	Since the effective MAO-B inhibitory and clinical dose of rasagiline is about one-tenth that of selegiline, administration of 1 mg kg(-1) day(-1) rasagiline resulted in moderate decreases in SBP, DBP, and MAP, which were significantly lower than those caused by the 10 mg kg(-1) day(-1) dose of selegiline.	rasagiline	146-156	monoamine oxidase B	Rattus norvegicus	20-25
15628826-0	2004	Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor.	rasagiline	64-74	monoamine oxidase B	Homo sapiens	114-138
15628826-12	2004	In the repeated-dose study, all doses of rasagiline were well tolerated; almost full inhibition of platelet MAO-B activity was achieved with each rasagiline dose.	rasagiline	41-51	monoamine oxidase B	Homo sapiens	108-113
15165835-1	2004	The modification of L-3,4-dihydrooxyphenylalanine- (L-DOPA-) induced turning response by the new selective monoamine oxidase type B (MAO-B) inhibitor rasagiline was studied in guinea-pigs bearing a unilateral 6-hydroxydopamine-induced lesion in the substantia nigra.	rasagiline	150-160	amine oxidase [flavin-containing] B	Cavia porcellus	107-131
15247150-2	2004	Using a model of serum deprivation, we investigated the mechanism by which the anti-Parkinson/monoamine oxidase (MAO)-B inhibitor drug, rasagiline, exerts its neuroprotective effect in rat pheochromocytoma PC12 cells.	rasagiline	136-146	monoamine oxidase B	Rattus norvegicus	94-119
15247150-3	2004	Here, we report that rasagiline (0.1-10 microM) decreased apoptosis via multiple protection mechanisms, including the stimulation of PKC phosphorylation; up-regulation of PKCalpha and PKC mRNAs, induction of Bcl-xL, Bcl-w, and brain-derived neurotrophic factor (BDNF) mRNAs; and down-regulation of Bad and Bax mRNAs.	rasagiline	21-31	protein kinase C, gamma	Rattus norvegicus	133-136
15247150-3	2004	Here, we report that rasagiline (0.1-10 microM) decreased apoptosis via multiple protection mechanisms, including the stimulation of PKC phosphorylation; up-regulation of PKCalpha and PKC mRNAs, induction of Bcl-xL, Bcl-w, and brain-derived neurotrophic factor (BDNF) mRNAs; and down-regulation of Bad and Bax mRNAs.	rasagiline	21-31	protein kinase C, alpha	Rattus norvegicus	171-179
15247150-3	2004	Here, we report that rasagiline (0.1-10 microM) decreased apoptosis via multiple protection mechanisms, including the stimulation of PKC phosphorylation; up-regulation of PKCalpha and PKC mRNAs, induction of Bcl-xL, Bcl-w, and brain-derived neurotrophic factor (BDNF) mRNAs; and down-regulation of Bad and Bax mRNAs.	rasagiline	21-31	protein kinase C, gamma	Rattus norvegicus	171-174
15247150-3	2004	Here, we report that rasagiline (0.1-10 microM) decreased apoptosis via multiple protection mechanisms, including the stimulation of PKC phosphorylation; up-regulation of PKCalpha and PKC mRNAs, induction of Bcl-xL, Bcl-w, and brain-derived neurotrophic factor (BDNF) mRNAs; and down-regulation of Bad and Bax mRNAs.	rasagiline	21-31	Bcl2-like 1	Rattus norvegicus	208-214
15247150-3	2004	Here, we report that rasagiline (0.1-10 microM) decreased apoptosis via multiple protection mechanisms, including the stimulation of PKC phosphorylation; up-regulation of PKCalpha and PKC mRNAs, induction of Bcl-xL, Bcl-w, and brain-derived neurotrophic factor (BDNF) mRNAs; and down-regulation of Bad and Bax mRNAs.	rasagiline	21-31	Bcl2-like 2	Rattus norvegicus	216-221
15247150-3	2004	Here, we report that rasagiline (0.1-10 microM) decreased apoptosis via multiple protection mechanisms, including the stimulation of PKC phosphorylation; up-regulation of PKCalpha and PKC mRNAs, induction of Bcl-xL, Bcl-w, and brain-derived neurotrophic factor (BDNF) mRNAs; and down-regulation of Bad and Bax mRNAs.	rasagiline	21-31	brain-derived neurotrophic factor	Rattus norvegicus	227-260
15247150-3	2004	Here, we report that rasagiline (0.1-10 microM) decreased apoptosis via multiple protection mechanisms, including the stimulation of PKC phosphorylation; up-regulation of PKCalpha and PKC mRNAs, induction of Bcl-xL, Bcl-w, and brain-derived neurotrophic factor (BDNF) mRNAs; and down-regulation of Bad and Bax mRNAs.	rasagiline	21-31	brain-derived neurotrophic factor	Rattus norvegicus	262-266
15247150-3	2004	Here, we report that rasagiline (0.1-10 microM) decreased apoptosis via multiple protection mechanisms, including the stimulation of PKC phosphorylation; up-regulation of PKCalpha and PKC mRNAs, induction of Bcl-xL, Bcl-w, and brain-derived neurotrophic factor (BDNF) mRNAs; and down-regulation of Bad and Bax mRNAs.	rasagiline	21-31	BCL2 associated X, apoptosis regulator	Rattus norvegicus	306-309
15247150-4	2004	Moreover, rasagiline inhibited the cleavage and activation of procaspase-3 and poly (ADP-ribose) polymerase (PARP), whereas the PKC inhibitor, GF109203X, reversed these actions.	rasagiline	10-20	poly (ADP-ribose) polymerase 1	Rattus norvegicus	62-107
15247150-5	2004	Similarly, rasagiline decreased serum-free-induced levels of the important regulator of cell death, Bad, which was also blocked by GF109203X, indicating the involvement of PKC in rasagiline-induced cell survival.	rasagiline	11-21	protein kinase C, gamma	Rattus norvegicus	172-175
15247150-5	2004	Similarly, rasagiline decreased serum-free-induced levels of the important regulator of cell death, Bad, which was also blocked by GF109203X, indicating the involvement of PKC in rasagiline-induced cell survival.	rasagiline	179-189	protein kinase C, gamma	Rattus norvegicus	172-175
15247150-6	2004	Furthermore, these studies have established that PKC- and Bcl-2-dependent neuroprotective activity of rasagiline is dependent on its propargyl moiety, because propargylamine had similar effects with the same potency.	rasagiline	102-112	protein kinase C, gamma	Rattus norvegicus	49-52
15247150-6	2004	Furthermore, these studies have established that PKC- and Bcl-2-dependent neuroprotective activity of rasagiline is dependent on its propargyl moiety, because propargylamine had similar effects with the same potency.	rasagiline	102-112	BCL2, apoptosis regulator	Rattus norvegicus	58-63
15300656-1	2004	Rasagiline (N-propargyl-1(R)-aminoindan) mesylate is a potent, selective, and irreversible monoamine oxidase-B inhibitor.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	91-110
15165835-1	2004	The modification of L-3,4-dihydrooxyphenylalanine- (L-DOPA-) induced turning response by the new selective monoamine oxidase type B (MAO-B) inhibitor rasagiline was studied in guinea-pigs bearing a unilateral 6-hydroxydopamine-induced lesion in the substantia nigra.	rasagiline	150-160	amine oxidase [flavin-containing] B	Cavia porcellus	133-138
15165835-10	2004	Activity of brain MAO-B was 8.6+/-2.9% and MAO-A was 71+/-1.5% that of control in rasagiline-treated animals.	rasagiline	82-92	amine oxidase [flavin-containing] B	Cavia porcellus	18-23
15165835-10	2004	Activity of brain MAO-B was 8.6+/-2.9% and MAO-A was 71+/-1.5% that of control in rasagiline-treated animals.	rasagiline	82-92	amine oxidase [flavin-containing] A	Cavia porcellus	43-48
15165835-11	2004	Chronic, selective inhibition of MAO-B by rasagiline potentiated L-DOPA-induced turning in this rodent model.	rasagiline	42-52	amine oxidase [flavin-containing] B	Cavia porcellus	33-38
15147504-1	2004	We have recently shown that the anti-Parkinson-propargyl-containing monoamine oxidase B (MAO-B) inhibitor drug, rasagiline [N-propargyl-(1R)-aminoindan], and its cholinesterase inhibitor derivatives TV3326 and TV3279, regulate amyloid precursor protein (APP) processing by a protein kinase C (PKC)-dependent mechanism in SH-SY5Y neuroblastoma and PC12 cells.	rasagiline	112-122	monoamine oxidase B	Homo sapiens	68-87
15144871-1	2004	Sprague-Dawley rats received a unilateral injection of 6-hydroxydopamine (6-OHDA) into the striatum and were treated daily for 6 weeks with increasing doses of monoamine oxidase type B inhibitor rasagiline [R(+)-N-propargyl-1-aminoindane] or saline (controls).	rasagiline	195-205	monoamine oxidase B	Rattus norvegicus	160-184
15147504-1	2004	We have recently shown that the anti-Parkinson-propargyl-containing monoamine oxidase B (MAO-B) inhibitor drug, rasagiline [N-propargyl-(1R)-aminoindan], and its cholinesterase inhibitor derivatives TV3326 and TV3279, regulate amyloid precursor protein (APP) processing by a protein kinase C (PKC)-dependent mechanism in SH-SY5Y neuroblastoma and PC12 cells.	rasagiline	112-122	monoamine oxidase B	Homo sapiens	89-94
15147504-1	2004	We have recently shown that the anti-Parkinson-propargyl-containing monoamine oxidase B (MAO-B) inhibitor drug, rasagiline [N-propargyl-(1R)-aminoindan], and its cholinesterase inhibitor derivatives TV3326 and TV3279, regulate amyloid precursor protein (APP) processing by a protein kinase C (PKC)-dependent mechanism in SH-SY5Y neuroblastoma and PC12 cells.	rasagiline	112-122	butyrylcholinesterase	Homo sapiens	162-176
15147504-1	2004	We have recently shown that the anti-Parkinson-propargyl-containing monoamine oxidase B (MAO-B) inhibitor drug, rasagiline [N-propargyl-(1R)-aminoindan], and its cholinesterase inhibitor derivatives TV3326 and TV3279, regulate amyloid precursor protein (APP) processing by a protein kinase C (PKC)-dependent mechanism in SH-SY5Y neuroblastoma and PC12 cells.	rasagiline	112-122	amyloid beta precursor protein	Homo sapiens	227-252
15147504-5	2004	The results also demonstrate that rasagiline treatment significantly elevated the levels of phosphorylated myristoylated alanine-rich C kinase substrate (p-MARCKS), a major substrate for PKC, as well as the levels of receptors for activated C kinase 1 (RACK1).	rasagiline	34-44	myristoylated alanine rich protein kinase C substrate	Homo sapiens	107-152
15147504-5	2004	The results also demonstrate that rasagiline treatment significantly elevated the levels of phosphorylated myristoylated alanine-rich C kinase substrate (p-MARCKS), a major substrate for PKC, as well as the levels of receptors for activated C kinase 1 (RACK1).	rasagiline	34-44	myristoylated alanine rich protein kinase C substrate	Homo sapiens	156-162
15147504-5	2004	The results also demonstrate that rasagiline treatment significantly elevated the levels of phosphorylated myristoylated alanine-rich C kinase substrate (p-MARCKS), a major substrate for PKC, as well as the levels of receptors for activated C kinase 1 (RACK1).	rasagiline	34-44	receptor for activated C kinase 1	Homo sapiens	217-251
15147504-5	2004	The results also demonstrate that rasagiline treatment significantly elevated the levels of phosphorylated myristoylated alanine-rich C kinase substrate (p-MARCKS), a major substrate for PKC, as well as the levels of receptors for activated C kinase 1 (RACK1).	rasagiline	34-44	receptor for activated C kinase 1	Homo sapiens	253-258
15147504-6	2004	Similar effects on APP and PKC levels were also demonstrated for the two cholinesterase inhibitor derivatives of rasagiline, TV3326 and TV3279.	rasagiline	113-123	butyrylcholinesterase	Homo sapiens	73-87
14687604-0	2004	N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor.	rasagiline	30-40	nuclear factor kappa B subunit 1	Homo sapiens	156-165
14687604-1	2004	N-Propargyl-l(R)-aminoindan, rasagiline, an anti-Parkinson drug, was found to increase the protein and mRNA levels of glial cell line-derived neurotrophic factor (GDNF) in human neuroblastoma SH-SY5Y cells, whereas an analogue without a propargyl residue, aminoindan, did not.	rasagiline	29-39	glial cell derived neurotrophic factor	Homo sapiens	118-161
14687604-1	2004	N-Propargyl-l(R)-aminoindan, rasagiline, an anti-Parkinson drug, was found to increase the protein and mRNA levels of glial cell line-derived neurotrophic factor (GDNF) in human neuroblastoma SH-SY5Y cells, whereas an analogue without a propargyl residue, aminoindan, did not.	rasagiline	29-39	glial cell derived neurotrophic factor	Homo sapiens	163-167
14687604-4	2004	Rasagiline induced phosphorylation of inhibitory subunit (IkappaB) of nuclear factor-kappaB (NF-kappaB), and translocation of active p65 subunit from cytoplasm into nuclei.	rasagiline	0-10	nuclear factor kappa B subunit 1	Homo sapiens	70-91
14687604-4	2004	Rasagiline induced phosphorylation of inhibitory subunit (IkappaB) of nuclear factor-kappaB (NF-kappaB), and translocation of active p65 subunit from cytoplasm into nuclei.	rasagiline	0-10	nuclear factor kappa B subunit 1	Homo sapiens	93-102
14687604-4	2004	Rasagiline induced phosphorylation of inhibitory subunit (IkappaB) of nuclear factor-kappaB (NF-kappaB), and translocation of active p65 subunit from cytoplasm into nuclei.	rasagiline	0-10	RELA proto-oncogene, NF-kB subunit	Homo sapiens	133-136
14687604-6	2004	Sulfasalazine, an inhibitor of IkappaB kinase, suppressed the activation of NF-kappaB and the increase of GDNF by rasagiline simultaneously, further indicating the involvement of the IkappaB kinase-NF-kappaB pathway.	rasagiline	114-124	glial cell derived neurotrophic factor	Homo sapiens	106-110
14687604-6	2004	Sulfasalazine, an inhibitor of IkappaB kinase, suppressed the activation of NF-kappaB and the increase of GDNF by rasagiline simultaneously, further indicating the involvement of the IkappaB kinase-NF-kappaB pathway.	rasagiline	114-124	nuclear factor kappa B subunit 1	Homo sapiens	198-207
15027867-5	2004	MAO B and MAO A are more selective for the R-enantiomer (rasagiline) compared to the S-enantiomer (S-PAI) by 2500-fold and 17-fold, respectively.	rasagiline	57-67	serpin family B member 2	Homo sapiens	101-104
14696044-6	2004	To circumvent this obstacle, a novel MAO-B inhibitor, rasagiline, was developed.	rasagiline	54-64	monoamine oxidase B	Homo sapiens	37-42
15027867-0	2004	Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.	rasagiline	73-83	monoamine oxidase A	Homo sapiens	43-69
15027867-4	2004	Rasagiline has the highest specificity for MAO B, as demonstrated by a 100-fold higher inhibition potency (k(inact)/K(i)) compared to MAO A, with the remaining compounds exhibiting lower isozyme specificities.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	43-48
15027867-5	2004	MAO B and MAO A are more selective for the R-enantiomer (rasagiline) compared to the S-enantiomer (S-PAI) by 2500-fold and 17-fold, respectively.	rasagiline	57-67	monoamine oxidase B	Homo sapiens	0-5
15027867-5	2004	MAO B and MAO A are more selective for the R-enantiomer (rasagiline) compared to the S-enantiomer (S-PAI) by 2500-fold and 17-fold, respectively.	rasagiline	57-67	monoamine oxidase A	Homo sapiens	10-15
15027867-6	2004	Differences in UV/vis and CD spectral data of the complexes of the studied compounds with both MAO A and MAO B are interpreted in light of crystallographic data of complexes of MAO B with rasagiline and its analogues (Binda, C.; et al.	rasagiline	188-198	monoamine oxidase B	Homo sapiens	105-110
15027867-6	2004	Differences in UV/vis and CD spectral data of the complexes of the studied compounds with both MAO A and MAO B are interpreted in light of crystallographic data of complexes of MAO B with rasagiline and its analogues (Binda, C.; et al.	rasagiline	188-198	monoamine oxidase B	Homo sapiens	177-182
14732458-1	2004	The anti-Parkinson selective irreversible monoamine oxidase B inhibitor drugs, rasagiline and selegiline, have been shown to possess neuroprotective activities in cell culture and in vivo models.	rasagiline	79-89	monoamine oxidase B	Rattus norvegicus	42-61
14732458-4	2004	Pretreatment of PC12 cells in absence of serum and NGF for 24 h with either rasagiline (1 microM) or selegiline (1 microM) is neuroprotective and anti-apoptotic as determined by ELISA and MTT tests.	rasagiline	76-86	nerve growth factor	Rattus norvegicus	51-54
14732458-7	2004	Recently it has been demonstrated that rasagiline directly activates PKC-MAP kinase pathway by a concentration and time dependent phosphorylation of p42 and p44 MAP kinase.	rasagiline	39-49	mitogen activated protein kinase 3	Rattus norvegicus	157-160
14732458-8	2004	In the present studies the neuroprotective activity of rasagiline is blocked by ERK inhibitor, PD98059 (20 microM), suggesting the involvement of PKC-MAP kinase pathway in the neuroprotection.	rasagiline	55-65	Eph receptor B1	Rattus norvegicus	80-83
14555244-0	2003	The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline.	rasagiline	148-158	BCL2 apoptosis regulator	Homo sapiens	20-25
14525944-1	2003	Rasagiline [N-propargyl-(1R)-aminoindan] a highly potent selective irreversible monoamine oxidase (MAO)-B inhibitor exerts neuroprotective and antiapoptotic effects against a variety of insults in cell cultures and in vivo and has finished its phase III clinical trials for Parkinson"s disease.	rasagiline	0-10	monoamine oxidase B	Rattus norvegicus	80-105
14525944-3	2003	In addition, rasagiline significantly increased (approximately threefold) the secretion of the nonamyloidogenic soluble form of the amyloid precursor protein (sAPPalpha) from SH-SY5Y neuroblastoma and PC12 cells.	rasagiline	13-23	amyloid beta precursor protein	Homo sapiens	132-157
14525944-5	2003	Rasagiline-induced sAPPalpha release was significantly reduced by the inhibitors of protein kinase C (PKC), GF109203X, and ERK mitogen-activated protein kinase (MAPK) PD98059.	rasagiline	0-10	mitogen activated protein kinase 3	Rattus norvegicus	123-126
14525944-6	2003	Moreover, rasagiline dose dependently (0.1-10 microM) increased the phosphorylation of p44 and p42 MAPK, which was abolished by PD98059 (30 microM) and GF109203X (2.5 microM).	rasagiline	10-20	mitogen activated protein kinase 3	Rattus norvegicus	87-90
14525944-6	2003	Moreover, rasagiline dose dependently (0.1-10 microM) increased the phosphorylation of p44 and p42 MAPK, which was abolished by PD98059 (30 microM) and GF109203X (2.5 microM).	rasagiline	10-20	mitogen activated protein kinase 1	Rattus norvegicus	95-103
19810877-3	2003	One such agent is the anti-Parkinson drug, rasagiline, a novel neuroprotective-antiapoptotic second-generation potent irreversible selective inhibitor of monoamine oxidase B.	rasagiline	43-53	monoamine oxidase B	Homo sapiens	154-173
14555244-0	2003	The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline.	rasagiline	148-158	proline rich transmembrane protein 2	Homo sapiens	27-30
14555244-1	2003	The anti-Parkinson drug, rasagiline, a irreversible propargyl possessing monoamine oxidase B inhibitor can protect neurons in vitro and in vivo from a variety of neurotoxic insults including SIN-1, glutamate, the parkinsonism inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, N-methyl-(R)-salsolinol and including beta amyloid protein.	rasagiline	25-35	monoamine oxidase B	Homo sapiens	73-92
14555244-1	2003	The anti-Parkinson drug, rasagiline, a irreversible propargyl possessing monoamine oxidase B inhibitor can protect neurons in vitro and in vivo from a variety of neurotoxic insults including SIN-1, glutamate, the parkinsonism inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, N-methyl-(R)-salsolinol and including beta amyloid protein.	rasagiline	25-35	MAPK associated protein 1	Homo sapiens	191-196
14555244-3	2003	Specifically rasagiline activates Bcl-2, Bcl-xl, protein kinase C (PKC) and reduces Bax in a variety of cells including PC-12 and neuroblastoma human dopamine derived SH-SY5Y cells.	rasagiline	13-23	BCL2 apoptosis regulator	Homo sapiens	34-39
14555244-3	2003	Specifically rasagiline activates Bcl-2, Bcl-xl, protein kinase C (PKC) and reduces Bax in a variety of cells including PC-12 and neuroblastoma human dopamine derived SH-SY5Y cells.	rasagiline	13-23	BCL2 like 1	Homo sapiens	41-47
14555244-3	2003	Specifically rasagiline activates Bcl-2, Bcl-xl, protein kinase C (PKC) and reduces Bax in a variety of cells including PC-12 and neuroblastoma human dopamine derived SH-SY5Y cells.	rasagiline	13-23	proline rich transmembrane protein 2	Homo sapiens	49-65
14555244-3	2003	Specifically rasagiline activates Bcl-2, Bcl-xl, protein kinase C (PKC) and reduces Bax in a variety of cells including PC-12 and neuroblastoma human dopamine derived SH-SY5Y cells.	rasagiline	13-23	proline rich transmembrane protein 2	Homo sapiens	67-70
14555244-3	2003	Specifically rasagiline activates Bcl-2, Bcl-xl, protein kinase C (PKC) and reduces Bax in a variety of cells including PC-12 and neuroblastoma human dopamine derived SH-SY5Y cells.	rasagiline	13-23	BCL2 associated X, apoptosis regulator	Homo sapiens	84-87
14555244-5	2003	This pharmacological action of rasagiline is also associated with the prevention of the neurotoxin induced fall in mitochondrial membrane potential, opening of mitochondria permeability transition pore, activation of proteasome-ubiquitin complex, inhibition of cytochrome c release and prevention of caspase 3 activation, similar to the actions of cyclosporin A or Bcl-2 over expression in SH-SY5Y cells.	rasagiline	31-41	cytochrome c, somatic	Homo sapiens	261-273
14555244-5	2003	This pharmacological action of rasagiline is also associated with the prevention of the neurotoxin induced fall in mitochondrial membrane potential, opening of mitochondria permeability transition pore, activation of proteasome-ubiquitin complex, inhibition of cytochrome c release and prevention of caspase 3 activation, similar to the actions of cyclosporin A or Bcl-2 over expression in SH-SY5Y cells.	rasagiline	31-41	caspase 3	Homo sapiens	300-309
14555244-5	2003	This pharmacological action of rasagiline is also associated with the prevention of the neurotoxin induced fall in mitochondrial membrane potential, opening of mitochondria permeability transition pore, activation of proteasome-ubiquitin complex, inhibition of cytochrome c release and prevention of caspase 3 activation, similar to the actions of cyclosporin A or Bcl-2 over expression in SH-SY5Y cells.	rasagiline	31-41	BCL2 apoptosis regulator	Homo sapiens	365-370
14555244-6	2003	Rasagiline and its various derivatives induces PKC dependent release of soluble amyloid precursor protein alpha and which is blocked by inhibitors of alpha-secretase, PKC and MAPK-dependent signaling.	rasagiline	0-10	proline rich transmembrane protein 2	Homo sapiens	47-50
14555244-6	2003	Rasagiline and its various derivatives induces PKC dependent release of soluble amyloid precursor protein alpha and which is blocked by inhibitors of alpha-secretase, PKC and MAPK-dependent signaling.	rasagiline	0-10	proline rich transmembrane protein 2	Homo sapiens	167-170
12871751-2	2003	The new monoamine oxidase-B inhibitor rasagiline is devoid of sympathomimetic effects and is metabolised to R(+)-1-aminoindan.	rasagiline	38-48	monoamine oxidase B	Rattus norvegicus	8-27
12943198-3	2003	The new N-propargyl-3-pyrrol-1-ylindanamine derivatives were evaluated for their potential MAO-B inhibitor activity in an in vivo model of MPTP-induced Parkinsonism in mice with respect to the potent MAO-B inhibitor rasagiline.	rasagiline	216-226	monoamine oxidase B	Mus musculus	200-205
12697291-2	2003	A series of novel propargylaminoindans with a carbamate moiety to inhibit cholinesterase were developed from phamacophore of rasagiline to protect or rescue deteriorated neurons in Alzheimer"s and Lewy Body disease and provide a beneficial effect on the cognitive deficits.	rasagiline	125-135	butyrylcholinesterase	Homo sapiens	74-88
12200198-7	2002	Rasagiline prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF).	rasagiline	0-10	BCL2 apoptosis regulator	Homo sapiens	108-113
12206996-0	2002	Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline.	rasagiline	132-142	amyloid beta precursor protein	Homo sapiens	47-72
12200198-7	2002	Rasagiline prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF).	rasagiline	0-10	glial cell derived neurotrophic factor	Homo sapiens	141-184
12200198-7	2002	Rasagiline prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF).	rasagiline	0-10	glial cell derived neurotrophic factor	Homo sapiens	186-190
12943198-0	2003	Synthesis and initial results for MAO-B inhibition by new N-propargyl-3-pyrrol-1-ylindanamine derivatives, analogues of rasagiline.	rasagiline	120-130	monoamine oxidase B	Mus musculus	34-39
12470183-2	2002	OBJECTIVE: To evaluate the safety and efficacy of the selective monoamine oxidase type B inhibitor rasagiline.	rasagiline	99-109	monoamine oxidase B	Homo sapiens	64-88
12504917-3	2002	Reserpine-induced ptosis was reversed by rasagiline at doses above 2 mg x kg(-1) i.p., which inhibit MAO-A as well as MAO-B, but not at MAO-B-selective doses.	rasagiline	41-51	monoamine oxidase A	Homo sapiens	101-106
12504917-3	2002	Reserpine-induced ptosis was reversed by rasagiline at doses above 2 mg x kg(-1) i.p., which inhibit MAO-A as well as MAO-B, but not at MAO-B-selective doses.	rasagiline	41-51	monoamine oxidase B	Homo sapiens	118-123
12433110-4	2002	The MAO-B inhibitory potency of (-)-deprenyl and (+)-rasagiline is also evaluated.	rasagiline	49-63	monoamine oxidase B	Mus musculus	4-9
12433110-6	2002	(+)-Rasagiline is found to be a more potent MAO-B inhibitor than (-)-deprenyl.	rasagiline	0-14	monoamine oxidase B	Mus musculus	44-49
12090555-2	2002	Rasagiline is a selective and potent irreversible MAO(B) inhibitor which is under development by Teva for the treatment of neurological diseases.	rasagiline	0-10	monoamine oxidase B	Homo sapiens	50-56
12358797-6	2002	Rasagiline, N-propargyl-1(R)-aminoindan, which is a now under a clinical trial for Parkinson"s disease, suppressed the DeltaPsim reduction, release of cytochrome c, and apoptosis induced by NM(R)Sal in SH-SY5Y cells.	rasagiline	0-10	cytochrome c, somatic	Homo sapiens	151-163
12057839-0	2002	An anti-Parkinson"s disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells.	rasagiline	63-73	BCL2 apoptosis regulator	Homo sapiens	114-119
12057839-3	2002	In this paper, the effects of rasagiline on the levels of anti-apoptotic bcl-2 gene family were studied.	rasagiline	30-40	BCL2 apoptosis regulator	Homo sapiens	73-78
12057839-4	2002	Rasagiline increased the levels of bcl-2 and bcl-x(l) mRNA at 100-10 nM and 100-10 pM, but not the level of pro-apoptotic bax mRNA.	rasagiline	0-10	BCL2 apoptosis regulator	Homo sapiens	35-40
12057839-4	2002	Rasagiline increased the levels of bcl-2 and bcl-x(l) mRNA at 100-10 nM and 100-10 pM, but not the level of pro-apoptotic bax mRNA.	rasagiline	0-10	BCL2 like 1	Homo sapiens	45-50
12057839-5	2002	Enhanced expression of bcl-2 family indicates the ability of rasagiline to adjust the apoptotic threshold and protect degenerating neurons in PD.	rasagiline	61-71	BCL2 apoptosis regulator	Homo sapiens	23-28
11462801-4	2001	All these compounds possess a propargyl moiety, which normally is responsible for irreversible inactivation of MAO, as is seen with rasagiline.	rasagiline	132-142	monoamine oxidase A	Rattus norvegicus	111-114
12044957-3	2002	We have therefore developed a number of novel drugs based on rasagiline (N-propargyl-1R-(+)-aminoindan), a potent anti-Parkinson-propargyl-containing MAO-B inhibitor drug with structural resemblance to selegiline, for the treatment of Alzheimer"s disease.	rasagiline	61-71	monoamine oxidase B	Homo sapiens	150-155
12039419-0	2002	Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson"s disease.	rasagiline	62-72	monoamine oxidase B	Rattus norvegicus	13-32
12039419-5	2002	A dose of 2.5 mg kg(-1) l-deprenyl and 1 mg kg(-1) rasagiline was shown to result in over 90% inhibition of the monoamine oxidase (MAO)-B from rat liver and striatum, whereas the inhibition of MAO-A was about 60 and 40% in liver and striatum, respectively.	rasagiline	51-61	monoamine oxidase B	Rattus norvegicus	112-137
12039419-5	2002	A dose of 2.5 mg kg(-1) l-deprenyl and 1 mg kg(-1) rasagiline was shown to result in over 90% inhibition of the monoamine oxidase (MAO)-B from rat liver and striatum, whereas the inhibition of MAO-A was about 60 and 40% in liver and striatum, respectively.	rasagiline	51-61	monoamine oxidase A	Rattus norvegicus	193-198
12043833-1	2001	Rasagiline (N-propargyl-1-(R)-aminoindan) is a selective, irreversible monoamine oxidase B (MAO B) inhibitor which has been developed as an anti-Parkinson drug.	rasagiline	0-10	monoamine oxidase B	Rattus norvegicus	71-90
12043833-1	2001	Rasagiline (N-propargyl-1-(R)-aminoindan) is a selective, irreversible monoamine oxidase B (MAO B) inhibitor which has been developed as an anti-Parkinson drug.	rasagiline	0-10	monoamine oxidase B	Rattus norvegicus	92-97
12043833-13	2001	Rasagiline interacts with and prevents the binding of PKI 1195 to the pro-apoptotic peripheral benzodiazepine receptor, which together with Bcl-2, hexokinase, porin, and adenine nucleotide translocator constitutes part of the VDAC.	rasagiline	0-10	BCL2, apoptosis regulator	Rattus norvegicus	140-145
12043833-16	2001	It is quite likely that the induction of Bcl-2 and activation of PKC by rasagiline and TV3326 is closely linked to the anti-apoptotic action of these drugs and their ability to process APP by activation of alpha-secretase.	rasagiline	72-82	BCL2, apoptosis regulator	Rattus norvegicus	41-46
11520893-0	2001	Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol.	rasagiline	71-81	glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens	115-155
11520893-8	2001	In addition, a novel antiparkinsonian drug, rasagiline, prevented nuclear accumulation of GAPDH induced by N-methyl(R)salsolinol in control cells.	rasagiline	44-54	glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens	90-95
11520893-9	2001	These results suggest that GAPDH may accumulate in nuclei as a consequence of signal transduction, which is antagonized by anti-apoptotic Bcl-2 protein family and rasagiline.	rasagiline	163-173	glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens	27-32
11462767-0	2001	Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs.	rasagiline	72-82	butyrylcholinesterase	Rattus norvegicus	33-47
11462767-1	2001	TV3326, (N-propargyl-(3R)-aminoindan-5-yl-ethyl,methyl carbamate) was prepared in order to combine the neuroprotective effects of rasagiline, a selective inhibitor of monoamine oxidase (MAO)-B with the cholinesterase (ChE) inhibitory activity of rivastigmine as a potential treatment for Alzheimer"s disease.	rasagiline	130-140	monoamine oxidase B	Rattus norvegicus	167-192
11956966-8	2002	The protection by rasagiline was proved to be due to stabilization of mitochondrial membrane potential against the collapse induced by SIN-1, whereas rasagiline did not scavenge peroxynitrite directly.	rasagiline	18-28	MAPK associated protein 1	Homo sapiens	135-140
11779573-1	2002	Selegiline and rasagiline are selective and irreversible monoamine oxidase-B inhibitors that exert neuroprotective effects in various preclinical models.	rasagiline	15-25	monoamine oxidase B	Rattus norvegicus	57-76
11462787-1	2001	Rasagiline and structurally related propargylamines protected dopaminergic SH-SY5Y cells from apoptosis induced by 6-OHDA and peroxynitrite-generating SIN-1.	rasagiline	0-10	MAPK associated protein 1	Homo sapiens	151-156
11462787-4	2001	The activation of apoptotic cascade by the oxidative stress and neurotoxins, such as activation of caspase 3 and DNA fragmentation, was also inhibited by pretreatment with rasagiline.	rasagiline	172-182	caspase 3	Homo sapiens	99-108
11795516-6	2001	Interestingly, we have recently shown that another propargylamine, rasagiline not only increases antioxidant enzyme activities (CAT and SOD) in brain dopaminergic regions as (-)deprenyl does, but also increases CAT and SOD activities in extrabrain catecholaminergic systems such as the heart and kidneys as well.	rasagiline	67-77	catalase	Rattus norvegicus	211-214
11795516-6	2001	Interestingly, we have recently shown that another propargylamine, rasagiline not only increases antioxidant enzyme activities (CAT and SOD) in brain dopaminergic regions as (-)deprenyl does, but also increases CAT and SOD activities in extrabrain catecholaminergic systems such as the heart and kidneys as well.	rasagiline	67-77	catalase	Rattus norvegicus	128-131
11159700-0	2001	Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.	rasagiline	0-10	monoamine oxidase B	Rattus norvegicus	93-112
11159700-2	2001	Rasagiline [N-propargyl-1R(+)-aminoindan], was examined for its monoamine oxidase (MAO) A and B inhibitor activities in rats together with its S(-)-enantiomer (TVP 1022) and the racemic compound (AGN-1135) and compared to selegiline (1-deprenyl).	rasagiline	0-10	monoamine oxidase A	Rattus norvegicus	64-95
11159700-5	2001	While rasagiline and AGN1135 are highly potent selective irreversible inhibitors of MAO in vitro and in vivo, the S(-) enantiomer is relatively inactive in the tissues examined.	rasagiline	6-16	monoamine oxidase A	Rattus norvegicus	84-87
11159700-5	2001	While rasagiline and AGN1135 are highly potent selective irreversible inhibitors of MAO in vitro and in vivo, the S(-) enantiomer is relatively inactive in the tissues examined.	rasagiline	21-28	monoamine oxidase A	Rattus norvegicus	84-87
11159700-7	2001	The in vitro IC(50) values for inhibition of rat brain MAO activity by rasagiline are 4.43+/-0.92 nM (type B), and 412+/-123 nM (type A).	rasagiline	71-81	monoamine oxidase A	Rattus norvegicus	55-58
11159700-8	2001	The ED(50) values for ex vivo inhibition of MAO in the brain and liver by a single dose of rasagiline are 0.1+/-0.01, 0.042+/-0.0045 mg kg(-1) respectively for MAO-B, and 6.48+/-0.81, 2.38+/-0.35 mg kg(-1) respectively for MAO-A.	rasagiline	91-101	monoamine oxidase A	Rattus norvegicus	44-47
11159700-8	2001	The ED(50) values for ex vivo inhibition of MAO in the brain and liver by a single dose of rasagiline are 0.1+/-0.01, 0.042+/-0.0045 mg kg(-1) respectively for MAO-B, and 6.48+/-0.81, 2.38+/-0.35 mg kg(-1) respectively for MAO-A.	rasagiline	91-101	monoamine oxidase B	Rattus norvegicus	160-165
11159700-8	2001	The ED(50) values for ex vivo inhibition of MAO in the brain and liver by a single dose of rasagiline are 0.1+/-0.01, 0.042+/-0.0045 mg kg(-1) respectively for MAO-B, and 6.48+/-0.81, 2.38+/-0.35 mg kg(-1) respectively for MAO-A.	rasagiline	91-101	monoamine oxidase A	Rattus norvegicus	223-228
11159700-12	2001	The degree of selectivity of rasagiline for inhibition of MAO-B as opposed to MAO-A was similar to that of selegiline.	rasagiline	29-39	monoamine oxidase B	Rattus norvegicus	58-63
11159700-13	2001	Rasagiline was three to 15 times more potent than selegiline for inhibition of MAO-B in rat brain and liver in vivo on acute and chronic administration, but had similar potency in vitro.	rasagiline	0-10	monoamine oxidase B	Rattus norvegicus	79-84
11716151-4	2001	Rasagiline (R-(+)-N-propyl-1-aminoindane) is a novel irrevesible MAO-B-inhibitor, which is not metabolized to metamphetamine and/or amphetamine.	rasagiline	0-10	monoamine oxidase B	Mus musculus	65-70
11716145-1	2001	The aim of this study was to determine whether chronic treatment with the selective MAO-B inhibitor rasagiline, N-propargyl-1-(R)-aminoindan (R-PAI), can prevent or delay stroke or improve its outcome in salt-loaded stroke-prone spontaneously hypertensive rats (SHRSP).	rasagiline	100-110	monoamine oxidase B	Rattus norvegicus	84-89
11575866-8	2000	Almost complete platelet MAO-B inhibition was obtained at all rasagiline doses.	rasagiline	62-72	monoamine oxidase B	Homo sapiens	25-30
11192605-1	2000	The neuronal survival properties of rasagiline (R(+)-N-propargyl-1-aminoindane mesylate or TVP-1012), a novel monoamine oxidase B inhibitor, have been investigated using neuronal cell cultures from fetal rat and human ventral mesencephalon.	rasagiline	36-46	monoamine oxidase B	Rattus norvegicus	110-129
10993123-0	2000	Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat.	rasagiline	20-30	catalase	Rattus norvegicus	59-67
10996018-2	2000	After long term administration to rodents, a propargylamine structurally related to (-)deprenyl, (R)(+)-N-propargyl-1-aminoindan (rasagiline) increased the activities of anti-oxidative enzymes, superoxide dismutase and catalase.	rasagiline	130-140	catalase	Homo sapiens	219-227
10996018-6	2000	Rasagiline prevented the loss of DeltaPsim, the initial step to apoptosis, and also following caspase 3-activation and DNA fragmentation.	rasagiline	0-10	caspase 3	Homo sapiens	94-103
10993123-1	2000	Rasagiline [N-propargyl-l(R)-aminoindan] is a selective irreversible MAO-B inhibitor as is (-)deprenyl.	rasagiline	0-10	monoamine oxidase B	Rattus norvegicus	69-74
10993123-6	2000	Two doses of rasagiline (0.5 mg/kg/day, 1.0 mg/kg/day, both for 3.5 weeks) significantly increased catalase activities about 2-fold in substantia nigra and striatum but not in hippocampus.	rasagiline	13-23	catalase	Rattus norvegicus	99-107
10518120-0	1999	Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen-glucose deprivation.	rasagiline	0-10	monoamine oxidase B	Rattus norvegicus	14-33
11205137-1	2000	TV3326, [(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate] is a novel aminoindan derivative of the selective irreversible monoamine oxidase (MAO)-B inhibitor, rasagiline (N-propargyl-(1R)-aminoindan), possessing both cholinesterase (ChE) and MAO-inhibitory activity.	rasagiline	168-178	monoamine oxidase B	Rattus norvegicus	131-156
11205137-1	2000	TV3326, [(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate] is a novel aminoindan derivative of the selective irreversible monoamine oxidase (MAO)-B inhibitor, rasagiline (N-propargyl-(1R)-aminoindan), possessing both cholinesterase (ChE) and MAO-inhibitory activity.	rasagiline	168-178	monoamine oxidase A	Rattus norvegicus	150-153
10518120-0	1999	Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen-glucose deprivation.	rasagiline	0-10	nerve growth factor	Rattus norvegicus	54-57
10518120-1	1999	In our in vitro model, rasagiline a selective irreversible monoamine oxidase-B (MAO-B) inhibitor, protected nerve growth factor (NGF)-differentiated PC12 cells from cell death under oxygen and glucose deprivation (OGD).	rasagiline	23-33	monoamine oxidase B	Rattus norvegicus	59-78
10518120-1	1999	In our in vitro model, rasagiline a selective irreversible monoamine oxidase-B (MAO-B) inhibitor, protected nerve growth factor (NGF)-differentiated PC12 cells from cell death under oxygen and glucose deprivation (OGD).	rasagiline	23-33	monoamine oxidase B	Rattus norvegicus	80-85
10518120-1	1999	In our in vitro model, rasagiline a selective irreversible monoamine oxidase-B (MAO-B) inhibitor, protected nerve growth factor (NGF)-differentiated PC12 cells from cell death under oxygen and glucose deprivation (OGD).	rasagiline	23-33	nerve growth factor	Rattus norvegicus	108-127
10518120-1	1999	In our in vitro model, rasagiline a selective irreversible monoamine oxidase-B (MAO-B) inhibitor, protected nerve growth factor (NGF)-differentiated PC12 cells from cell death under oxygen and glucose deprivation (OGD).	rasagiline	23-33	nerve growth factor	Rattus norvegicus	129-132
10518120-10	1999	As NGF-differentiated PC12 cells contain exclusively MAO type A, these data suggest that the neuroprotective effect of rasagiline under OGD conditions is independent of MAO inhibition.	rasagiline	119-129	nerve growth factor	Rattus norvegicus	3-6
9632221-1	1998	Rasagiline (N-propargyl-1(R)aminoindan) is a selective and potent MAO-B inhibitor currently under development as the mesylate salt (TVP-1012) for the treatment of various neurologic disorders.	rasagiline	0-10	monoamine oxidase B	Rattus norvegicus	66-71
10082192-0	1999	Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse.	rasagiline	26-36	monoamine oxidase B	Mus musculus	50-69
10907720-0	1999	Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat.	rasagiline	13-23	monoamine oxidase B	Rattus norvegicus	27-32
10907720-1	1999	Rasagiline, as the mesylate salt (TVP-1012), is a selective, potent, non-reversible MAO-B inhibitor of the propargylamine type.	rasagiline	0-10	monoamine oxidase B	Rattus norvegicus	84-89
1797336-11	1991	The release of catecholamines from chromaffin cells in response to milacemide (10(-4) M) was partially inhibited by the selective MAO-B inhibitors (-)-deprenyl (10(-7) M) and AGN 1135 (10(-6) M).	rasagiline	175-183	monoamine oxidase B	Bos taurus	130-135
9559942-0	1998	Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor.	rasagiline	46-56	monoamine oxidase B	Rattus norvegicus	60-79
9564627-0	1998	Chronic TVP-1012 (rasagiline) dose--activity response of monoamine oxidases A and B in the brain of the common marmoset.	rasagiline	18-28	amine oxidase [flavin-containing] A	Callithrix jacchus	57-83
9564628-0	1998	Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey.	rasagiline	139-149	monoamine oxidase B	Macaca mulatta	85-104
9564629-1	1998	N-propargyl-1-(R)aminoindan (rasagiline) is a new and selective irreversible MAO-B inhibitor, currently being considered as the mesylate salt for potential therapy in certain neurological disorders.	rasagiline	29-39	monoamine oxidase B	Rattus norvegicus	77-82
9564630-0	1998	(R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B.	rasagiline	33-43	monoamine oxidase B	Homo sapiens	104-123
8988465-1	1996	Rasagiline [R(+)-N-propargyl-1-aminoindane] is a selective irreversible inhibitor of MAO-B which is not metabolised to amphetamine-like derivatives.	rasagiline	0-10	monoamine oxidase B	Rattus norvegicus	85-90
34784871-11	2021	Of monoamine oxidase B inhibitors, safinamide is the least susceptible for interaction with the tyramine-rich food, whereas selegiline and rasagiline may lose selectivity to monoamine oxidase B when administered in supratherapeutic doses.	rasagiline	139-149	monoamine oxidase B	Homo sapiens	174-193
34977548-4	2022	Therefore, we determined whether rasagiline, a common MAO-B inhibitor used in PD treatment, can contribute to cardiovascular autonomic BP dysregulation in patients with early or mild PD.	rasagiline	33-43	monoamine oxidase B	Homo sapiens	54-59
34562673-4	2021	A selectivity study over hMAO-A revealed an excellent selectivity index of compound 5 (SI > 2375) with a 47-fold increase compared to rasagiline (II, a well-known MAO-B inhibitor, SI > 50).	rasagiline	134-144	monoamine oxidase B	Homo sapiens	163-168
33818516-9	2021	All the tested compounds were capable to inhibit human monoamine oxidase-B enzyme to a significant extent, however, compound 7 exerted the most prominent inhibitory activity, similar to selegiline and rasagiline.	rasagiline	201-211	monoamine oxidase B	Homo sapiens	55-74
34352710-3	2021	Compound 20 exhibited the best activity and selectivity towards hMAO-B with IC50 value of 53 nM and selectivity index of 1122 folds over MAO-A, compared to the reference drugs rasagiline (IC50 = 66 nM) and selegiline (IC50 = 40 nM).	rasagiline	176-186	monoamine oxidase B	Homo sapiens	64-70
34679775-7	2021	When compared to the modest selectivity index of rasagiline (II, a well-known MAO-B inhibitor, SI > 50), compounds 7b, 8a, 8b and 8e showed remarkable selectivity indices (SI > 305, 3649, 3278, and 220, respectively).	rasagiline	49-59	monoamine oxidase B	Rattus norvegicus	78-83
34679739-7	2021	When compared with the modest selectivity index of rasagiline (II, a well-known MAO-B inhibitor, SI > 50), compounds 3n, 3r, 3u, and 3v demonstrated better selectivity indices (SI > 71, 109, 83, and 151, respectively).	rasagiline	51-61	monoamine oxidase B	Rattus norvegicus	80-85
35447344-2	2022	Two propargylamine-containing MAO-B inhibitors, selegiline ((R)-deprenyl) and rasagiline, are currently used in the clinic for this purpose.	rasagiline	78-88	monoamine oxidase B	Homo sapiens	30-35
34290084-5	2021	Both inhibition of MAO-B by selegiline or rasagiline and siRNA-mediated knockdown of MAO-B facilitated alpha-syn secretion.	rasagiline	42-52	monoamine oxidase B	Homo sapiens	19-24
34290084-5	2021	Both inhibition of MAO-B by selegiline or rasagiline and siRNA-mediated knockdown of MAO-B facilitated alpha-syn secretion.	rasagiline	42-52	synuclein alpha	Homo sapiens	103-112
35480532-0	2022	Rasagiline Pharmacokinetics in CYP1A2 Variant Healthy Smokers & Non-smokers in Different Doses.	rasagiline	0-10	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	31-37
35480532-1	2022	Objectives: Rasagiline, a drug for Parkinson"s disease is metabolized by CYP1A2 enzyme.	rasagiline	12-22	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	73-79
35480532-2	2022	The objective of the study was to investigate the influence of cytochrome P450 1A2 variants and smoking status of healthy individuals on the pharmacokinetics of rasagiline.	rasagiline	161-171	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	63-82
35480532-13	2022	Conclusion: The study concludes that the systemic metabolism of rasagiline is significantly increased in CYP1A2*AA variants while smoking status did not show consistent difference in PK parameters.	rasagiline	64-74	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	105-111
35203982-4	2022	To date, no DRT-related withdrawal syndrome has been described in PD patients who discontinue rasagiline, an irreversible inhibitor of monoamine oxidase-B (MAO-B).	rasagiline	94-104	monoamine oxidase B	Homo sapiens	135-154
35203982-4	2022	To date, no DRT-related withdrawal syndrome has been described in PD patients who discontinue rasagiline, an irreversible inhibitor of monoamine oxidase-B (MAO-B).	rasagiline	94-104	monoamine oxidase B	Homo sapiens	156-161
6793119-0	1981	Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B.	rasagiline	36-44	monoamine oxidase B	Rattus norvegicus	75-99
35447344-4	2022	An important consideration is that selegiline and rasagiline display specificity for MAO-B over the MAO-A isoform thus reducing the risk of tyramine-induced changes in blood-pressure.	rasagiline	50-60	monoamine oxidase B	Homo sapiens	85-90
35447344-4	2022	An important consideration is that selegiline and rasagiline display specificity for MAO-B over the MAO-A isoform thus reducing the risk of tyramine-induced changes in blood-pressure.	rasagiline	50-60	monoamine oxidase A	Homo sapiens	100-105
35301652-6	2022	Rasagiline also increased Tnf-alpha, IL1beta, IL6, NF-kappabetaand HMGB1 gene expressions in dose-dependent at 2 mg/kg and 4 mg/kg doses.	rasagiline	0-10	tumor necrosis factor	Rattus norvegicus	26-35
35301652-6	2022	Rasagiline also increased Tnf-alpha, IL1beta, IL6, NF-kappabetaand HMGB1 gene expressions in dose-dependent at 2 mg/kg and 4 mg/kg doses.	rasagiline	0-10	interleukin 1 alpha	Rattus norvegicus	37-44
35301652-6	2022	Rasagiline also increased Tnf-alpha, IL1beta, IL6, NF-kappabetaand HMGB1 gene expressions in dose-dependent at 2 mg/kg and 4 mg/kg doses.	rasagiline	0-10	interleukin 6	Rattus norvegicus	46-49
35301652-6	2022	Rasagiline also increased Tnf-alpha, IL1beta, IL6, NF-kappabetaand HMGB1 gene expressions in dose-dependent at 2 mg/kg and 4 mg/kg doses.	rasagiline	0-10	high mobility group box 1	Rattus norvegicus	67-72
3499585-4	1987	Like MPTP, MCTP was a good substrate for monoamine oxidase-B (MAO-B) and its neurotoxicity was prevented in mice by AGN-1135, a selective inhibitor of MAO-B.	rasagiline	116-124	monoamine oxidase B	Mus musculus	41-60
3499585-4	1987	Like MPTP, MCTP was a good substrate for monoamine oxidase-B (MAO-B) and its neurotoxicity was prevented in mice by AGN-1135, a selective inhibitor of MAO-B.	rasagiline	116-124	monoamine oxidase B	Mus musculus	62-67
3499585-4	1987	Like MPTP, MCTP was a good substrate for monoamine oxidase-B (MAO-B) and its neurotoxicity was prevented in mice by AGN-1135, a selective inhibitor of MAO-B.	rasagiline	116-124	monoamine oxidase B	Mus musculus	151-156
2420928-5	1986	N-Desmethylpropargylindane hydrochloride (AGN 1135) was also shown to have MAO-B inhibitory selectivity similar to that of l-deprenyl.	rasagiline	42-50	monoamine oxidase B	Homo sapiens	75-80
3935467-0	1985	Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B.	rasagiline	57-65	monoamine oxidase B	Mus musculus	91-110